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ABSTRACT 
 
The presence of virulent, pathogenic bacteria in our body, food, water and other 
consumables is harmful and causes enormous economic and personal losses. Here we will be 
looking at developing a platform technology that can rapidly detect pathogenic bacteria. The 
platform will be based on an electrical spectroscopic method called microchannel Electrical 
Impedance Spectroscopy (m-EIS). Initially, we will look at the growth of bacteria as our primary 
method to detect the presence of bacteria and find the time-to-detection. Following this, we will 
study the death of bacteria in a suspension using our technique of m-EIS to reduce the time-to-
detection further. We want to detect the pathogenic Mycobacteria Tuberculosis (that causes 
Tuberculosis in humans), which according to WHO, is the second leading cause of death due to 
infectious diseases. As proof of concept, surrogates like Mycobacterium bovis BCG and 
Mycobacterium smegmatis will be taken up for detection using our technique of m-EIS. However, 
our first focus is to prevent surgical site infections. 
Transmission of contagious infections like tuberculosis or infections occurring post-
surgery like surgical site infections can be reduced and prevented, to some extent by proper 
treatment and correct use of antibiotics. For example, surgical site infection, occurring after 
insertion of implants can be reduced by use of coatings and other surface modifications. Many of 
these amendments ensure prevention of bacterial adhesion and kill surrounding bacteria near the 
implant. Further, in some cases, they promote the growth of desired cells that warrants proper 
integration of the implants with the bone. Surgical site infections occurring post-surgery can be 
reduced by following proper preoperative skin preparations. Several techniques are applied in the 
hospitals like 2-step scrubbing and painting, 2-step scrubbing and drying, and 1-step painting with 
xviii 
 
a drying time. However, most of these techniques are time-consuming and labor-intensive. Here, 
we have demonstrated that the antimicrobial efficacy of a spray-on formulation containing 
Betadine is comparable to the existing techniques. The spray-on Betadine formulation is 
significantly less time-consuming and is not labor-intensive. 
Though prevention is necessary, often time, the pathogens have to be detected and 
identified as early as possible. In recent times, several molecular, serological and proteomic-based 
methods have been developed. However, these methods have several disadvantages such as they 
are expensive, labor-intensive, bulky, among others. The culture-based techniques are considered 
the gold standard. Though sensitive, they too suffer from inherent disadvantages of long time-to-
detection. Hence, there is an urgent need for the development of rapid and cost-effective techniques 
for detection and identification of bacterial pathogens. 
Here, we present an approach that can detect the presence of viable microorganisms in 
suspensions, much faster than culture-based technique. The existing automated culture-based 
systems detect the metabolic changes in the growth media and the environment of the bottles 
containing the media (parameters monitored like pH, Oxygen, Carbon Dioxide among others) that 
change as the bacteria proliferates. As this changes in pH, Oxygen and others can be minuscule, a 
large number of bacteria is needed before the changes can be detected. This increases the time-to-
detection significantly for culture-based techniques. Our technique, microchannel Electrical 
Impedance Spectroscopy (m-EIS), relies on the fact that on the application of an AC electric field 
to a bacterial suspension, the viable bacterial cells become polarized and store charges due to the 
presence of intact cell membranes. As a result, they behave as electrical capacitors. Any change in 
the number of bacterial cells in the suspension (like growth or death of cells) is reflected by a 
concomitant shift in the storage of bacterial charges and capacitance of the bulk. Due to the unique 
xix 
 
geometry of the measuring device (microfluidic cassettes) used by us, we can distinguish between 
the capacitance arising due to the bacterial cells and that of the parasitic double layer capacitance.   
A practical application of this technique has been found to be useful for detection of 
clinically significant slow-growing mycobacterial cultures. Most of the automated culture-based 
systems available in the market are based on the measurement of the growth dynamics of the 
microorganisms. However, as the generation time of the slow growing bacteria is long, these 
systems take a long time (6-8 weeks) to generate results. With the use of our m-EIS measurement 
technique, we can reduce the times-to-detection by ~50%. 
Further, we observed that the time-to-detection is further reduced by monitoring cell death 
in real time using our technique. As only living entities can be killed, our technique can detect the 
presence of viable cells in a suspension by monitoring their death. It has been observed that using 
our technique following the death dynamics is much faster than growth dynamics. The death of 
microorganisms that have long generation times like mycobacteria can be achieved by use of 
antibiotics (depending on which antibiotics and its concentration) at a much faster rate than their 
growth in a nutrient media. Real-time monitoring of death shows a decrease in the bulk capacitance 
values which provides us the time-to-detection much more rapidly. 
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CHAPTER 1 
1 INTRODUCTION 
1.1 Motivation 
Bacteria is ubiquitous. Though most bacteria are harmless, some are virulent and 
can cause diseases. These harmful, pathogenic bacteria may be present in our body, food, 
water and other consumables and can cause huge damage and losses. For examples, 
pathogens in the human body like Escherichia coli, Salmonella, Staphylococcus aureus, 
Psedumonas aeruginosa, Mycobacterium tuberculosis, result in infections and contagious 
diseases like food poisoning, wound infections, toxic shock syndrome, meningitis, 
tuberculosis, and eventually, may lead to morbidity and mortality (1). Among the top ten 
leading causes of death in 2011, World Health Organizations (WHO) identifies infectious 
and parasitic diseases, lower respiratory tract infections and tuberculosis as the second, 
third and seventh leading causes of mortality (2). These infections also result in significant 
production losses.  
Recent developments in the manufacture of food products and other consumables 
involve techniques like pasteurization, canning, which have led to the reduction of harmful 
bacteria. However, some hardy bacteria like Listeria monocytogenes, Clostridium 
botulinum etc. survive these techniques and cause spoilage of food products. These bacteria 
often lead to an outbreak of illness and epidemic diseases amongst people consuming the 
contaminated products. Recent estimates show that these can result in loss of about 1 billion 
dollars each year (3). Mead et. al found that contaminated food products result in 76 million 
foodborne illness and about 5000 deaths in the United States alone (4).  
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Thus, there is an urgent need for proper detection, characterization, identification 
and treatment of diseases caused by bacterial pathogens. Proper detection and identification 
of pathogens become significantly complicated as in many cases they do not have definitive 
clinical manifestation. This also makes early screening difficult (1). Moreover, most times 
it is difficult to differentiate between closely related species.  
Current gold standard for detection of bacteria is culturing techniques. The 
culturing technique involves growing bacteria in liquid or solid media, and either measure 
the colonies formed or the various growth indicators like metabolic products produced, pH 
changes, etc. over the extended incubation period. Recent molecular methods based on 
genomics and proteomics have significant advantages over conventional culture-based 
techniques; that is, they do not involve lengthy incubation period and thereby reduce the 
time for analysis (5, 6). However, these methods are expensive and in many cases often 
cannot distinguish between viable and non-viable bacteria.  
Rapid identification and detection of bacteria are essential for public health and 
clinical diagnosis. In some cases, bacterial identification can influence the course of 
treatment and decrease the propagation of antibiotic resistant bacteria and hence, the spread 
of infection. In case of foodborne illness, the detection techniques need to be rapid so that 
the contaminated products is removed from public to prevent an epidemic. There is also a 
need for rapid detection of biological warfare agents in case of bioterrorism (2). Hence, 
recent focus has shifted to rapid detection and identification of pathogenic bacteria and 
their control/elimination in public health, clinical and environmental settings and food 
safety monitoring (5).  
1.2 Healthcare-associated infections (HAIs)  
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During treatment, infections may occur in hospitalized patients being treated for 
other illnesses (7). This transmission of infection in hospitalized patients may be due to 
various reasons like their weak immune systems or the invasive procedures being 
performed on them or the poor infection control procedures in the hospitals and are known 
as Healthcare-associated infections. HAIs not only increase patient mortality and morbidity 
but also prove to be an enormous economic burden to the patients. It often leads to patient 
inconvenience and loss of productivity. HAIs include central line-associated bloodstream 
infections (CLABI), catheter-associated urinary tract infections (CAUTI), ventilator-
associated pneumonia (VAP), surgical site infections (SSI) and Clostridium difficile-
associated disease (CDI) (8). Centers for Disease Control and Prevention (CDC) tracks the 
HAIs occurring in the healthcare system and provides guidelines to prevent/ reduce the 
number of incidences occurring (9). Scott et. al has estimated the overall cost of treating 
HAIs as approximately 4.5 HAIs for every 100 hospital admissions to about $6.65 billion 
dollars in 2007 (post correction of inflation) (8).  
It has been estimated that about 50% of HAIs is preventable (10). So, it can be seen 
that there is significant scope for improvement and reduction in the number of HAIs and 
to save lives. Although it is not possible to emphasize on all area of HAIs, we have 
attempted here to reduce the number of infections occurring due to SSIs. In chapter 2, the 
SSIs occurring due to orthopedic implants is studied. Though these SSIs are less common, 
they are more difficult to treat as they need long and stringent antibiotic treatments and 
may need surgical procedures (11).  
Over the years, there has been a tremendous increase in the usage of orthopedic 
implants for short term or long term to assist in the normal function of the human body. 
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The usage of implants has been found to be increasing with increasing life expectancy and 
also, due to the increase in the number of accidents and injuries resulting from our modern 
and dynamic lifestyle. Other factors involved include an increase in public awareness and 
availability of improved/ better medical procedures. After being introduced in the body, 
these implants encounter various body fluids like blood, proteinaceous matter, and cells 
present in the body. Often these interactions lead to the development of biofilms at the site 
of implants and result in infections. Also, it can result in improper osseointegration. Both 
of these conditions might delay patient recovery, lead to extreme morbidity and sometimes 
in mortality.  
To treat SSI resulting from implants,  clinicians either rely on the usage of 
antibiotics or debridement techniques or in some cases, use a combination of both. 
Therefore, researchers are looking for techniques, which will slow the onset of infections 
while improving osseointegration. An ideal preventive method should be able to prevent 
biofilm formation and kill the infection-causing bacteria surrounding the implant while 
help in the healing process. In Chapter 2 the current implant surface modification and 
coating techniques that are available which prevent infection are examined in depth. The 
contents chapter 2 have been published as a manuscript entitled “Coatings and surface 
modifications imparting antimicrobial activity to orthopedic implants” in the journal 
Nanomedicine and Nanobiotechnology.  
The occurrence of SSIs after any surgery is of concern, be it orthopedic or any other 
surgery. Among all nosocomial infections, SSI accounts for about 20% of infections, and 
the estimated cost of treating SSIs is about 10 billion dollars (8, 12-14). Bacteria can enter 
a patient’s body through the operation site (15). Healthcare providers try and prevent SSIs 
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through a combination of techniques. Common techniques that are used before any surgery 
involves sterilization of operating rooms, proper cleaning, and de-hairing of the surgical 
site and cleaning of surgical sites using antibiotics. Some of the commonly used antibiotics 
involve Iodine, Betadine, alcohol, among others (16).  
Chapter 3, compares an in-house antibiotic spray-on protocol to the 5-minute 
antibiotic scrub protocol which is commonly used for surgical site preparation (17).  The 
results from the in-vitro testing of the spray-on surgical site preparation method on both 
agar plates and porcine skin are compared to the scrub protocol. The contents of chapter 3 
have been published as a manuscript entitled “ Foaming Betadine Spray as a potential agent 
for non-labor-intensive preoperative surgical site preparation” in Annals of Clinical 
Microbiology and antimicrobials. 
1.3 Emerging Infectious Diseases 
 Pathogenic microorganisms (bacteria, fungi, viruses, parasites) are responsible for 
causing various infectious diseases in humans (18). These diseases are contagious and can 
be transmitted by direct (coming in contact with an infected person) or indirect means 
(spread by a vector).  Researchers have used the term emerging infectious diseases to define 
infections that are newly appearing in humans or are rapidly spreading amongst humans or 
are widespread in any geographic areas (19, 20). Some of the examples of infectious 
disease involve multidrug-resistant tuberculosis, pandemic influenza, HIV/AIDS, severe 
acute respiratory syndrome (SARS) (21). If undetected, these diseases lead to economic 
losses, social stigma, widespread fear, morbidity, and mortality. According to the Report 
on Infectious Diseases published by WHO in 1999, out of the 54 million deaths happening 
due to various causes, about 13 million deaths were solely due to infectious diseases (18). 
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The bulk of the deaths resulted from pneumonia, diarrheal diseases, and tuberculosis (7.2 
million deaths) (22).  
 According to the 2012 Global Report for Research on Infectious Diseases of 
Poverty, 1 billion people are affected by one or more infectious diseases. The economic 
impact of these diseases is felt even by those who are not struck by the disease. The 
economic impact is widespread as can be seen from reports which estimate losses due to 
SARS to be 50-140 billion dollars while that due to N1H1 to be about 2.7-4.5 billion dollars 
(23).  
 However, the emergence of infectious disease can be avoided or controlled and 
cured by proper treatment using antibiotics (24). Misdiagnosis and overuse of antibiotics 
have often resulted in antibiotic resistance in the causative organisms. Hence, there is an 
urgent need for rapid and timely detection as well as proper and effective treatment of 
infectious diseases.  
Tuberculosis is considered to be the second deadliest infectious disease after HIV. 
In 2012, about 1.2 million people died due to tuberculosis (25). Tuberculosis can be 
prevented and cured by timely diagnosis and proper treatment. Between 1995 and 2011, 
about 51 million lives had been saved by effective treatment strategy adopted by WHO 
(25). However, the microbiological detection and drug susceptibility of tuberculosis are 
critical and take a long time when culture-based methods are adopted. Currently, automated 
culture-based techniques are mainly used to detect the presence of viable bacteria and 
considered to be the gold standard. However they have long time-to-detections. The use of 
electrical impedance spectroscopy (EIS), where AC voltage is applied to bacterial 
suspension enables us to significantly reduce the time taken to detect mycobacteria. The 
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basics  of EIS are given in Chapter 4.  
Mycobacteria is very different from other bacteria as is described in detail in 
Chapter 5. Mycobacteria have mycolic acid present in their cell walls, and as a result, they 
are resistant to decolorization by acids and gram staining cannot be done for them (26). 
Usually, the acid-fast stain is performed to estimate the presence of mycobacteria in a 
sample where they are stained red and appear as long rod-shaped species under a 
microscope. In addition, due to long doubling times of mycobacteria the time to detection 
is very long on culture-based techniques.  
 Chapter 6, compares the times-to-detection for estimating the presence of 
mycobacteria in an in-vitro commercially available fully automated MGIT 960 system 
against our technology, based on electrical impedance spectroscopy (EIS). Commercial 
culture-based systems study and record the bacterial growth based on their metabolic 
products produced or by detecting a change in the system due to the metabolic products. 
Our system studies the change in the bulk capacitance of the system over time, which is an 
indication of the bacterial dynamics in the system. In this chapter, we demonstrate that our 
system has lower times to detection that is considerably lower than that obtained by the 
automated culture based systems. The contents of chapter 6 have been submitted as a 
manuscript entitled “Rapid culture-based detection of living Mycobacteria using 
microchannel Electrical Impedance Spectroscopy” to Biological Research Journal. 
 Chapter 7 is based on the fact that since only living entities can be killed, an 
approach that can detect the death of microorganisms should confirm the presence of viable 
organism. Most of the commercially available techniques detect the presence of 
mycobacteria based on the growth of the bacterial colonies or their metabolism/ growth 
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signature. However, we have seen that impedance spectroscopy can detect both growth and 
death of bacteria over time. By following the real time death of organism using EIS, the 
time-to-detection becomes dependent not on the growth dynamics but on how fast the 
organisms can be killed.  
1.4 Current gold standard for microorganism detection  
 For health care personnel to treat his/her patients, they need medical knowledge to 
be supported by patient history, clinical microbiology laboratory facts and 
pharmacokinetics of antibiotics (27). Blood cultures are the current gold standard available 
for clinicians for detection of viable microorganisms (27, 28). Efforts have been made to 
implement automated culture-based diagnostic platforms which have high sensitivity and 
need minimum human intervention.  
 There are several automated systems currently available in the market like 
BacT/AlertTM from BioMeriux, BactecTM from BD, ESPTM from Difco for blood culture 
tests while MGIT 960 system from BD, VersaTrek Mycobacteria detection system from 
VersaTrek for mycobacterial detection. When a sample containing viable bacteria is loaded 
into these instruments, the bacteria in the presence of nourishment (growth media) tend to 
grow, metabolize and increase in numbers. These automated devices monitor the 
metabolites generated, or they measure the changes in the system due to the generated 
metabolites to infer the presence of viable bacteria. Hence, the time to detection for these 
instruments is directly related to the doubling time of the microorganism. Longer the 
doubling time, the longer will be the time to detection, resulting in a delay in initiation of 
treatment.  
The only disadvantage associated blood culture techniques is a long period taken 
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to detect viable organisms. However, with recent advances, several novel, non-culture-
based techniques like PCR, molecular probes, have been developed. These techniques 
though much faster, are expensive and need specialization. Moreover, unlike the culture-
based diagnostic techniques, these non-culture based techniques can perform limited drug 
susceptibility testing. To reduce and prevent infections, rapid detection, and timely 
treatment is of paramount importance.  
 In addition to blood, several other samples of sputum, stool, can be tested.  For 
example, to detect tuberculosis, the sputum obtained from the patient is decontaminated to 
kill all other bacteria and then the decontaminated sputum is cultured to estimate the 
presence of viable bacteria. As the causative organism, Mycobacterium tuberculosis, is a 
very slow growing mycobacteria, with a growth time of ~24 hours, the culture techniques 
may take weeks to become positive. The cultures are held on for 6-8 weeks before being 
deemed negative. Hence, culture-based diagnosis can take anywhere from 3 days for blood 
culture works to ~6- 8 weeks for mycobacterial detection. As identification of organism is 
delayed, proper treatment is delayed. During this period the patient is typically 
administered broad spectrum antibiotics which result in antibiotic resistant organisms. This 
also results in an increase in patient morbidity and mortality. 
 Therefore, there is an urgent need to develop a culture-based technique that is 
highly sensitive and can rapidly determine the presence of viable microorganisms while 
reducing the time necessary to do so. Thereby, we can initiate faster and proper treatment 
of the patients.  
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CHAPTER 2 
2 COATINGS AND SURFACE MODIFICATIONS IMPARTING ANTIMICROBIAL 
ACTIVITY TO THE ORTHOPEDIC IMPLANTS 
The material presented in this chapter was reviewed and published as “Coatings and 
surface modifications imparting antimicrobial activity to orthopedic implants” 
Roli Kargupta, Sangho Bok, Charles M. Darr, Brett D. Crist, Keshab Gangopadhyay, 
Shubhra Gangopadhyay and Shramik Sengupta 
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2014. 6(5): p. 475-95. 
 
Bacterial colonization and biofilm formation on an orthopedic implant surface is 
one of the worst possible outcomes of orthopedic intervention in terms of both patient 
prognosis and healthcare costs. Making the problem even more vexing is the fact that 
infections are often caused by events beyond the control of the operating surgeon and may 
manifest weeks to months after the initial surgery. Herein, we review the costs and 
consequences of implant infection as well as methods of prevention and management. In 
particular, we focus on coatings and other forms of implant surface modification in a 
manner that imparts some antimicrobial benefit to the implant device. Such coatings can 
be classified generally based on their mode of action: surface adhesion prevention, 
bactericidal, antimicrobial-eluting, osseointegration promotion, and combinations of the 
above. Despite several advances in the efficacy of these antimicrobial methods, a 
remaining major challenge is ensuring retention of the antimicrobial activity over a period 
of months to years post-operation, an issue that has so far been inadequately addressed.  
Finally, we provide an overview of additional figures of merit that will determine whether 
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a given antimicrobial surface modification warrants adoption for clinical use.   
2.1 Introduction   
 Orthopedic implants are widely used devices in orthopedic surgery to provide rigid 
support for fractured bones and joint augmentation or replacement for pain relief and 
improved function. A plethora of orthopedic implants has been developed including 
fracture fixation devices (e.g. intramedullary nails, pins, plates, screws) and prosthetic 
joints (e.g. partial and full knee, hip, and shoulder). Once inserted, orthopedic implants 
may be required to function for decades (i.e. arthroplasty). During this time, implant 
materials not only come into intimate contact with various bodily fluids, proteinaceous 
matter, and host cells but also are expected to integrate and bond with the surrounding 
osseous tissue.  Failed or Incomplete osseointegration is often associated with the presence 
of bacteria, which form an impenetrable biofilm that initiates host immune responses.  If 
left unchecked, infection ultimately leads to tissue morbidity at the bone-implant interface 
and implant failure (29). Staphylococcus species account for nearly 30% of all implant 
infections, which not only threaten the implant and affected bone, but can result in systemic 
infection and loss of life and limb if not judiciously identified and managed (30-33). 
Compounding this issue is the drastic rise in usage rates in the last 20 years as a result of 
increasing trends in life expectancy, higher quality-of-life expectations, patient confidence 
in implant procedures, and improved surgical techniques. The 2010 National Health 
Discharge Survey by the Centers for Disease Control and Prevention (CDC) reported over 
719,000 total knee arthroplasty (TKR), 332,000 total hip arthroplasty (THR), and 438,000 
fracture surgeries with internal fixation increased from 129,000 TKR, 119,000 THR, and 
305,000 fracture reduction surgeries in 1990 (34, 35). This staggering number represented 
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a 2010 global annual market for orthopedic implant devices of more than $30 billion with 
a compounded annual growth rate (CAGR) of 8.2% (36), providing an expected market of 
more than $50 billion by 2018. Despite modern advances in aseptic technique, surgical site 
infections (SSIs) remain a major challenge in the world of orthopedics (30). According to 
the National Healthcare Safety Network (NHSN), SSIs occurred after 1.12% of orthopedic 
procedures between January 2006 and December 2009 (37). However, certain classes of 
implants are more prone to infection than others; fracture fixation devices report ~5% 
infection rate (11). SSIs increase the need for costly and potentially life-threatening 
revision surgeries with revision THR increasing by 3.7 procedures per 100,000 persons 
per decade and revision TKR by 5.4 procedures per 100,000 persons per decade (38). 
 Diagnosis and treatment of orthopedic infections can be quite challenging as the 
symptoms vary widely from patient to patient and may be mistaken for other conditions 
since they include some general indications:  pain, tenderness, local warmth, fever, foul 
odor, and fluid discharge (32). Routine blood work may reveal systemic inflammation 
through elevated C-reactive proteins (CRP) or white blood cell count but does not elucidate 
the cause. These may still be elevated in the early postoperative course. More accurate tests 
such as joint aspiration or blood cultures can identify specific microorganisms but may 
take 2-5 days depending on the species and required tests. Furthermore, there is a potential 
for the aspirate to have been a false-negative (39). Radiological imaging techniques (e.g. 
X-ray, computer tomography (CT), magnetic resonance imaging (MRI), ultrasound) may 
be helpful, but may not show changes until the infection is extensive and imaging studies 
are expensive (33). More recently, polymerase chain reaction (PCR) DNA amplification 
and sequencing techniques have been used, but have limited sensitivity and specificity and 
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have long incubation and detection times (40). In the meantime, the patient is given 
potentially unnecessary, contraindicated, or counterproductive medications, resulting in 
increased healthcare costs and bacterial antibiotic resistance. Typical primary treatment on 
identification involves surgical revision including debridement of the infected tissue 
coupled with the use of both local and systemic antibiotics. However, infection recurs in at 
least ~36% of cases (41). Repeated and prolonged infection indicates complete surgical 
implant removal and replacement, which again increases both patient suffering and 
healthcare costs (32). Given the severity of these undesired outcomes, perhaps the most 
appropriate way to confront bacterial infection is through proactive measures that 
simultaneously prevent bacterial colonization and promote osseointegration. This review 
will provide an overview of the current state-of-art information addressing these critical 
needs through implant device surface modification and surface coatings as well as their 
role in preventing implant-related infections. 
2.2 Biology of Orthopedic Infections 
Significant study has been devoted to the interaction of biofilm-forming bacteria with 
host cells and implanted devices, though some questions remain unanswered (42, 43). It 
should first be noted that successful orthopedic device implantation is an inherently 
difficult process even in the absence of bacteria since the host immune system immediately 
recognizes the implant surface as “foreign” and induces the formation of a proteinaceous 
layer to promote wound healing. However, if bacteria happen to be present as a result of 
previous or de novo infection, this proteinaceous matter acts as a conditioning layer that 
enhances bacterial adhesion. An experimental investigation has suggested that biofilm 
formation is a five-step process (Figure 2-1) (44). Initial bacterial attachment to the implant 
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surface is mediated through either non-specific (e.g. hydrophobic or van der Waals 
interactions) interactions with the proteinaceous layer or specific interactions such as those 
involving the Staphylococcus aureus (S. aureus) surface protein autolysin (Figure 2-1a) 
(45, 46).  Once securely anchored to the surface through irreversible attachment, bacteria 
proliferate at a rate governed by the availability of nutrients and oxygen as well as their 
Figure 2-1  A pictographic representation of the steps in bacterial biofilm formation 
using a Pseudomonas aeruginosa case study (44). (a) Bacteria adhere loosely and 
reversibly to the surface by non-specific binding, (b) Bacteria attach irreversibly to 
the surface and begin forming cell clusters, (c) Accumulation – Multiple layers of 
bacteria form and EPS layer provides protection to bacterial community, (d) 
Maturation - Biofilm reaches maximum thickness, and cells communicate via 
quorum sensing, and (e) Dispersion – Clusters detach and infection spreads to new 
areas. (Reprinted with permission from Ref [44]. Copyright 2003 Nature Publishing 
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intrinsic metabolism (Figure 2-1b).  After a region of the implant surface reaches a certain 
numerical cell density, physiological changes are induced in the bacteria that lead to the 
formation of a “biofilm,” a protective matrix composed of extracellular polymeric 
substance (EPS) (Figure 2-1c) (42, 47). Depending on the bacterial strain and local 
environmental conditions, the EPS may consist of exopolysaccharides, proteins, 
glycoproteins, glycolipids, teichoic acids, and extracellular DNA (42, 47). The micro-
ecosystem formed within the hydrated biofilm matrix is resistant to antibiotics, detergents, 
phagocytosis and other human immune system responses and further enables the 
interiorized cells to communicate through quorum sensing (Figure 2-1d) (44, 48). During 
the final step, the previously protected bacteria detach from the biofilm, migrate to a new 
area, and colonize the surrounding surfaces, resulting in spread of infection (Figure 2-1e).  
Pathogen dispersal from the biofilm can be truly devastating to patient health, leading to 
life-threatening downstream diseases ranging from endocarditis to sepsis (49).  
2.3 Approaches to Prevent and Manage Orthopedic Infections 
Pathogenic bacteria most often enter the host body at three critical periods: traumatic 
lacerations at the time of the incident, at the date of procedure, or during postoperative 
healing (50). Preoperative infections occurring in other parts of the body should also be 
identified and under control to prevent the possibility of hematogenous infections (51). The 
probability of implant infection can be reduced significantly by eliminating preoperative 
sources of bacterial contamination. Common preoperative strategies to reduce infection 
during implantation include hand cleaning by surgeons with alcohol-based antimicrobial 
agents, and preoperative antimicrobial skin preparations, commonly but not always, 
followed by patient hair removal at the incision site (52, 53). Other factors that need to be 
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taken into consideration include instrument sterilization, operating room air quality, use of 
laminar airflow systems, controlling the entry and exit of personnel from the operating 
room, and sterile gowns and uniforms (51, 54). Preoperative administration of antibiotic 
prophylaxis has also been found to be effective in reducing infections (51, 54). A recent 
study by Rao et al. showed that found that S. aureus positive THR/TKR patients receiving 
intranasal mupirocin and chlorhexidine experienced no SSIs within a two-year follow-up 
period (54). However, patient non-compliance with drug administration results in about 
10% of hospital admissions related to implant site infection, reducing the overall 
effectiveness of this technique significantly (55). 
Table 2.1: The different categories of orthopedic infections based on time of infection with 
respect to the operation. 
Category 
of 
infection 
Time 
period 
Causative agent Symptoms Treatment 
Early (33, 
56-58) 
<3 
months  
Virulent bacteria (e.g. 
S. aureus)  
Pain, fever, 
swelling, tender 
wounds 
Antibiotics; no 
surgery required 
Delayed 
(33, 56) 
 
Three 
months 
to 2 
years 
Small number of low-
virulence bacteria (e.g. 
coagulase-negative 
Staphylococci) 
Acute 
inflammation, 
infection, implant 
loosening 
observed 
Antibiotics 
ineffective even 
with surgical 
intervention (e.g. 
debridement) 
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Late (49, 
50)   
>2 years Hematogeneous 
infections caused by 
bacterial colonies 
present in dental, 
urinary, or respiratory 
systems 
Severe pain 
 
Surgical 
intervention 
 
 
Orthopedic infections can be organized into three distinct categories based on the 
time of infection on the operation:  early, delayed, and late (Table 2.1) (56). The risk of 
bacterial infection is typically highest immediately following implant placement, 
especially when tissues are exposed to trauma.  Early infections manifest within three 
months of implantation and result from virulent bacteria such as S. aureus (57). Symptoms 
associated with early infections include pain, fever, swelling, surgical site tenderness and 
drainage.  These can be potentially treated with antibiotics and sometimes implant retention 
is possible. For arthroplasty, the polyethylene components are typically exchanged.  
However, early infections may still result in chronic and systemic infection if left untreated 
(33, 58). Meanwhile, delayed infections manifest between 3 to 12 months post-operation 
with some authors extending this period to 24 months (33, 56). These are associated with 
acute inflammation and severe pain but may include implant loosening and sepsis.  Delayed 
infection can result from either a very low number of initial infecting bacteria, unfavorable 
growth conditions, or low-virulence bacteria (e.g. coagulase-negative Staphylococci) (56, 
57). These infections normally do not respond well to antibiotics even after surgical 
debridement of the affected tissue. Implant removal, surgical debridement, and local 
antibiotic delivery systems (antibiotic cement) is standard for arthroplasties.  As long as a 
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fracture is still healing and the fracture implants are still stable, the implant retention is 
attempted. Late infections manifest at least two-years post-operation.  These are typically 
latent hematogenous infections resulting from bacterial colonies already present in the 
dental, urinary, or respiratory systems.  
Infection classification by postoperative period is important in developing a 
treatment strategy, but cannot be the sole basis for the decision.  Other factors impacting 
the course of treatment include patient medical conditions and preference, surgical 
procedure and implant type, type and location of tissue infected, species of infecting 
organisms, infection severity at the time of detection, and inherent patient resistance to 
infection (11, 32, 57). The procedure suggested depends on the patient ability to endure 
treatment, including the increased cost, discomfort or disability, and hospital stay.  
Antimicrobial therapy is essential to combat infection (59, 60). In fact, doctors may prefer 
a more conservative antibiotic treatment to surgery in cases when the patient’s medical 
conditions preclude the ability to tolerate multiple surgeries.  The most common antibiotics 
prescribed are cephalosporins, oxacillin, and vancomycin.  However, local antibiotic 
resistance patterns vary and may require input from local infectious disease specialists. 
Some of the surgical approaches adopted include implant retention with 
debridement, implant removal with staged replantation, and arthrodesis/amputation.  
Debridement comprises the removal of damaged or infected tissue surrounding a well-fixed 
implant.  In this case, the implant is retained, and antibiotics are provided to prevent the 
spread of further infection (33), but there is no consensus as to the type or duration of 
antibiotic therapy (61). This treatment is suitable for patients with early postoperative 
infections with intact implants and confirmed pathogenic species.  A higher failure rate has 
19 
 
been demonstrated in cases of debridement and retention where symptoms of infection 
persisted for more than one week before treatment or if a sinus tract was present (62).   
Moreover, the probability of infection recurrence is ~54% in prosthetic joint infections due 
to S. aureus, likely a result of the virulence of this strain (63). Implant revision is a one- or 
two-stage surgical procedure to remove and replace an infected implant.  In the one-stage 
procedure, the infected implant is removed, infected tissue is debrided, and a new implant 
is inserted immediately.  The one-step procedure is indicated only for those patients who 
cannot withstand the physical demands of the two-step procedure.  The two-stage version 
is more common than others. In this version, the implant is removed and local antibiotics, 
such as antibiotic-impregnated cement, are placed in addition to systemic antibiotics. 
Typically, the second stage of replantation occurs after a six-week course of antibiotics is 
completed and normalization of the inflammatory markers occurs. However, this is 
dependent upon the pathogenic organism and may be delayed for a year for gram-negative 
organisms. The delay between debridement and implant insertion has been demonstrated 
to be a crucial factor in the success of the revision implantation, but the duration of the 
delay varies (32, 64). Delays ranging from 4 weeks to 3 months have been reported (65). 
Antibiotic-impregnated spacers have proven effective in reducing hospital stay duration 
and increasing patient mobility after THR (65). Vergidis et al. further observed the lower 
incidence of infection in cases of revision hip arthroplasty in which antibiotics were 
administered both systematically and in a bone cement (60). Typically, arthrodesis or 
amputation are reserved for patients with severe or recurrent infections and are more 
common in patients with severe medical problems (66). These are typically seen as last 
resort. 
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Antibiotic administration and surgical intervention are only necessary if the 
infection is present.  A more desirable option would be proactive prevention of bacterial 
colonization to circumvent infection altogether.  Engineering the implant surface to provide 
some antimicrobial or osseointegration benefit is one line of development that has been 
taken up in recent years. Essential characteristics of well-designed implants include 
porosity to enable strong bony ingrowth (i.e. osseointegration) (67) in long-term implants 
but prevent bony ingrowth in short-term implants, appropriate mechanical strength and 
elasticity to match the host tissue, low surface friction, corrosion resistance, ability to 
reduce inflammation, improved tribology, and reduced bacterial adhesion to the surface.  
In many ways, reducing bacterial adhesion and improving osseointegration are inherently 
coupled since there is surface binding competition between bacteria and host bone cells.  
Forming a strong bone-implant bond requires the formation of an apatite layer at the bone-
implant interface (29). Proper osseointegration not only allows for swift patient recovery 
but also prevents implant migration and failure.   
A variety of approaches has been attempted to improve osseointegration while 
simultaneously reducing infection and include: modifying implant surface energy, surface 
charge, composition, surface morphology and roughness, as well as the addition of 
functional surface coatings (68). In the following sections, we will report on the critical 
advancements being made in antimicrobial implant surface coatings and their effectiveness 
at preventing or mitigating the severity of bacterial infections and reducing patient recovery 
time. A particular emphasis will be placed on coating longevity or use life. While this 
information is not always readily available, we believe this property will have a significant 
impact on which technologies will gain wider acceptance shortly.  
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2.4 Antimicrobial Coatings  
A wide variety of functional antimicrobial coatings is already available on the market 
today. Some examples of FDA-approved implant coatings include INFUSETM bone graft 
from Medtronic (69), CarriGen porous bone substitute material from ETEX (70), Cerasorb 
from Curasam (71), and Spineplex P Bone Cement from Stryker (72, 73). Many others are 
at various stages of development and testing for regulatory approval. In this review, we 
classify antimicrobial coatings into five general categories based on their method of 
intervention in the infection and biofilm formation process: (1) Coatings that physically 
Figure 2-2 A schematic illustrating the various modes of action of different coatings and 
surface modifications. (a) Prevention of bacterial adhesion is possible due to physical 
actions like presence of polymer brush, (b) Prevention of bacterial adhesion owing to the 
presence of a sacrificial layer which do not allow the bacteria to adhere to the surface, (c) 
Killing of bacteria  due to the release of antimicrobial agents to the surrounding regions, 
(d) Killing of adherent bacteria owing to the presence of antimicrobial agents present on 
the surface and (c) Promotion and acceleration of desired cells which competes with the 
bacteria to promote osseointegration and  prevent colonization. 
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prevent bacterial adhesion, (2) Coatings that kill adherent bacteria, (3) Coatings that release 
antimicrobial agents to the surrounding region, (4) Coatings that accelerate adherence of 
desired cells (osteocytes), and (5) Coatings presenting more than one mode of action. A 
schematic illustrating the general principles of different coatings is shown in Figure 2-2.  
A summary of the various coatings and surface modifications imparting antimicrobial 
activity to orthopedic implants and their duration of efficacy can be found in Table 2.2. 
2.4.1 Coatings that prevent bacterial adhesion 
The first approach to preventing infection is to prepare a surface that microbes find 
difficult to colonize in the first place. This can be achieved through some ways including 
biodegradable surfaces to slough off adhered bacteria, and adhesion-resistant coatings as 
will be detailed below.  
2.4.1.1 Sacrificial coatings 
Modifying the implant surface with a sacrificial layer that dissolves away after a 
short time can be used to draw out any bacteria that had adhered to the original surface 
(74). Some biodegradable polymers have been used to this effect including polylactide (75, 
76), glycolides (77), and lactones (78).  Most resorbable polymers are designed to degrade 
within 9–10 weeks followed by controlled drug release for a subsequent 2–3 weeks (74). 
More recently, Wang et al. reported a degradable multilayer anti-adhesive coating using 
polyvinylpyrrolidone/poly(acrylic acid) (PVP/PAA) on top of a pre-existing multilayer 
antimicrobial coating of heparin/chitosan (HEP/CHI) (79). Thermal crosslinking the 
multilayer PVP/PAA films for specific periods are used to modulate the degradation rate 
(Figure 2-3).  Complete degradation of the top PVP/PAA multilayer film occurred within 
24 hours, after which the underlying multilayer antibacterial HEP/CHI film remained and 
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continued to supply benefit to the implant. This layer-by-layer technique showed 
significant promise toward multi-functional time-release coatings but requires more work 
before the extensive clinical application will be feasible. 
2.4.1.2 Adhesion-resistant coatings 
One of the approaches to prevent an infection from developing is to prepare a 
surface to which microbes find it hard to become strongly attached via chemical bonds.  
They include polyethylene glycol (PEG), diamond-like carbon (DLC), and polymer 
brushes as explained below. 
1. Unstructured polymer coatings 
Polyethylene glycol (PEG, [CH2CH2O]n) was first used for inhibition of microbial 
adhesion by introducing to modified polyurethane surfaces (80). Bacterial resistance by 
PEG-modified or “PEGylated” surfaces results from some material properties such as PEG 
chain density, length, and conformation. Proper selection of these properties allows the 
polymer to retain interfacial water, which does not favor microbial adhesion. Furthermore, 
PEG is resistant to compressive forces due to its tendency to remain in extended coil 
conformation and dynamic chain movement (80-82). PEGylated surfaces effectively 
inhibit microbial adhesion by up to a 3 log unit reduction in attached microbes, and is also 
effective in reducing adherent proteins and mammalian cells (82). Other hydrophilic 
polymers such as poly(2-hydroxyethyl methacrylate) (83) and phosphoryl choline-based 
polymers (84) also resist protein adsorption.  The creation of PEGylated surfaces requires 
multi-step synthesis. PEG-based surface treatment has developed as a self-assembled 
monolayer (SAM), polymer brush, and hydrogel (81).  
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2. Polymer brush coatings 
Polymer brushes exhibit some useful properties for anti-adhesive coatings such as 
excellent long-term stability, chemical robustness, biocompatibility, and controllable 
thickness (85, 86). Polymer brushes are assemblies of one or more polymers with one side 
tethered to the implant surface using either the “graft-to” or “graft-from” approach (Figure 
2-4).  The “grafting-to” approach employs a preformed polymer with a reactive end group 
while the “grafting from” approach involves building up the polymer in situ.  Grafting-to 
typically produces low polymer densities due to steric hindrance. On the other hand, 
grafting-from typically results in high-density self-assembled monolayers (SAMs).  
Furthermore, polymer brushes can differ from linear to branched, like star-shaped, and 
from homopolymers to block-copolymers.  Details about the grafting can be found in other 
literature (85-88).  
Polymer brushes have been used in some medical applications including diagnostics, 
cell culture, scaffolds for tissue engineering, and orthopedic implants, the latter of which 
titanium (Ti) and its alloys are typically employed (86).  Ren et al. demonstrated the use of 
polymer brushes on Ti surfaces (89). Ti was first coated with a SAM of the initiator (ω-
mercaptoundecyl Bromo isobutyrate) and then the polymer Polyoligo-(ethylene glycol) 
methacrylate-r-2-hydroxyethyl methacrylate [Poly(OEGMA-r-HEMA)]. The modified 
surface was resistant to cell adhesion, but further immobilization of recombinant human 
bone morphogenetic protein-2 induced adhesion of MC3T3 cells. Similarly, Anagnostou 
et al. demonstrated that functionalized poly(methyl methacrylate) (PMMA)-based 
terpolymers inhibited more than 90% of S. aureus adhesion compared to untreated surfaces 
(90). Guo et al. (91) recently demonstrated an interesting emerging technique of three-
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Figure 2-3 Schematic representation of multilayer biodegradable films produced by 
a layer-by-layer deposition method.  Multiple layers of (heparin/chitosan)-
(polyvinylpyrrolidone/poly(acrylic acid))x  [(HEP/CHI)x−(PVP/PAA)x], where ‘x’ 
denotes the number of layers, are constructed based on electrostatic interaction for 
HEP/CHI and hydrogen bond interaction for PVP/PAA, followed by thermal 
treatment at 110 °C for 16 h for crosslinking to form anhydride groups. In simulated 
physiological condition (e.g. PBS buffer at 37 °C), (PVP/PAA)10 layers were 
degradable in 24 hours, leading to almost no bacterial adhesion. After degradation 
of (PVP/PAA) layers, the underlying (HEP/CHI)x layers displayed contact killing of 
bacteria (79). (Reprinted with permission from Ref [79]. Copyright 2013 American 
Chemical Society) 
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dimensional (3D) printing polymer brushes.  Due to the heavy use of polymeric materials 
in most 3D printing, the 3D printed devices may not be feasible for biomedical purposes if 
these polymers are prone to bacterial colonization.  However, Guo prepared a 3D printing 
resin by integrating with a vinyl-terminated initiator, which allows the 3D printed device 
to be grafted with desired polymer brushes (3-sulfopropyl methacrylate (SPMA)) by 
surface-initiated atom transfer radical polymerization (SI-ATRP). Gram-negative 
(Escherichia coli, ATCC 29425) and Gram-positive (Bacillus subtilis, ATCC 6633) 
bacteria were used and no visible colonization in 24 hours incubation was reported.  
3. Diamond-like carbon coatings 
Diamond-like carbon (DLC) is an amorphous carbon thin film initially developed 
and used as a protective coating in hard drive disks and recently adapted for biological 
applications including biocompatible surface coatings for implant devices (92). DLC 
benefits from a low friction, high wear resistance, chemical inertness, and optical 
transparency while also cheap and facile to produce.  It has been reported that DLC coatings 
showed anti-adhesive characteristics when used as a coating on stainless steel. A 
comparison of bacterial adhesion to DLC-coated and uncoated stainless steel showed 
approximately 6 × 106 CFU/cm2 reduction in Pseudomonas aeruginosa adhesion (93).  
DLC coatings may also be doped with material species such as silver or copper particles, 
yielding antimicrobial properties in addition to the anti-adhesive properties (94). 
2.4.2 Coatings that kill adherent bacteria 
It is unlikely a coating can ensure that not even a single bacterium will adhere to it.  
A different approach is to devise coatings that will kill any bacterium that does adhere.  
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Figure 2-4 A) A substrate modified by grafting to approach in which the initially 
adsorbed polymer impedes further deposition, resulting in a low density of brushes. 
B) Modification of a substrate by the grafting of the approach in which an initiator-
bearing substrate is exposed to the monomer to afford thick, dense polymer brushes 
(86). C) Schematic of grafting poly(SPMA) on the 3D printed structures (91): to 
initiate atom transfer radical polymerization (ATRP), the Br-containing vinyl-
terminated initiator [2-(2-bromoisobutyryloxy)ethyl methacrylate (BrMA)] was pre-
mixed with the resin consisting of acrylate-based pre-polymers, crosslinking agents, 
and a phosphine oxide-based photoinitiator.  The acrylate-terminated polymers were 
utilized to incorporate with the initiator to achieve covalent bonding, and BrMA was 
used without affecting the photopolymerization during 3D printing processes. (A, B): 
Reprinted with permission from Ref [86]. Copyright 2009 American Vacuum 
Society, C: Reprinted with permission from Ref [91]. Copyright 2013 Royal Society 
of Chemistry) 
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Some different types of coatings try to employ this method and will be discussed below.  
2.4.2.1 Photoactive coatings 
Titanium and its alloys are commonly used in orthopedic implants due to their 
excellent mechanical properties, corrosion resistivity, and biocompatibility. As such, 
titanium dioxide that forms on exposed titanium surfaces has been studied extensively for 
beneficial properties photocatalytic activity that can potentially kill adherent microbes.  
This effect was first demonstrated by Matsunaga et al., which showed 100% effectiveness 
against 103 CFU/ml Saccharomyces cerevisiae and 103 CFU/ml E. coli after 2 hours UV 
illumination (95). Evonik Industries (formerly Degussa) P25 manufactures the TiO2 most 
widely used in antimicrobials research, consisting of an 80:20 anatase: rutile TiO2 crystal 
structure, specific surface area of 50 ± 15 m2/g, which was employed in the first 
demonstration of antimicrobial activity of TiO2 by Matsunaga et al (95). In addition, many 
researchers prepare the TiO2 materials by chemical vapor deposition (CVD) or sol-gel to 
improve the antimicrobial efficacy. Other approaches involve including metal additives 
such as copper and silver (96, 97). Sunada et al. (97) demonstrated the antimicrobial effect 
of Cu/TiO2 materials under indoor UV irradiation (a few hundred nW/cm
2), which is about 
three orders of magnitude weaker than outside UV sources.  The reactive species generated 
by the TiO2 under weak UV radiation opened the outer membrane (Figure 2-5b) so that the 
Cu ions penetrated into the cytoplasmic membrane (Figure 2-5c). The TiO2 photocatalytic 
reaction assists the intrusion of the Cu ions into the cell, which is why the Cu/TiO2 film 
was effective against E. coli even under feeble UV light (97).  These results, however, were 
reported under continuous UV radiation for several hours, which is infeasible for implants.  
2.4.2.2 Metal-impregnated surface coatings 
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Various metal-impregnated coatings, including silver and copper, have been 
assessed in both in-vitro and in-vivo studies for the potential to decrease implant 
colonization.  Metals identified as having antimicrobial activity include silver (Ag), copper 
oxide (Cu2O, CuO), zinc oxide (ZnO), titanium dioxide (TiO2), and tungsten oxide (WO3).  
Ag is the most common in the literature resulting from the good antimicrobial activity, low 
toxicity, and established commercial use in ex vivo applications. The primary Ag 
bactericidal mechanism is through disruption of the bacterial cell membrane and metabolic 
protein function by binding to DNA and thiolated proteins.  Ag-impregnated polymers have 
been successfully shown to protect the inner and outer surfaces of devices as antimicrobial 
coatings (98). Giglio et al. (99) demonstrated the antibacterial activity of electro-
Figure 2-5 Schematic illustrating bactericidal process for E. coli cells on Cu/TiO2 
thin film under weak UV light irradiation (96). (a) E. coli cell membranes are 
shown, (b) reactive species generated by the TiO2 photocatalyst attack and open the 
outer membrane, and (c) Cu ions effectively penetrate into the cell cytoplasmic 
membrane, resulting in cell lysis. (Reprinted with permission from Ref [96]. 
Copyright 2003 American Chemical Society)    
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synthesized Ag nanoparticle (AgNP)-modified poly(ethylene glycol diacrylate)–co–
acrylic acid (PEGDA-AA) hydrogel coatings on a Ti substrate, including both Gram-
positive (S. aureus) and Gram-negative (P. aeruginosa) species.  Further, AgNP-modified 
coatings showed no cytotoxicity toward human MG63 osteoblast-like cells after one week.  
Recently, Orlicki et al. (100) developed a AgNP-modified self-segregating hyperbranched 
polymer (HBP) polyurethane coating in which the AgNP migrate to the surface with time.  
The diffusion-limited spontaneous AgNP migration was enhanced by more than sevenfold 
using HBPs functionalized with thiol-terminated additives with associated 6-log reduction 
in P. aeruginosa, S. aureus, and the yeast Candida albicans.  Colon et al. (101) showed a 
Figure 2-6 (a) Schematic showing the antimicrobial effect of a porous sol-gel 
coating incorporating a silver ion (Ag+)-generating “ionosol” on E. coli cells, (b) 
Cross-sectional SEM images of the antimicrobial coatings revealing porous 
structure throughout the coating (102). (Reprinted with permission from Ref [102]. 
Copyright 2012 American Chemical Society) 
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simultaneous decrease in Staphylococcus epidermis adhesion and increase in osteoblast 
adhesion on nanostructured ZnO and TiO2 when compared with micro-structured surfaces.  
Ionic liquids have also been used to enhance AgNP-impregnated coatings with a choice of 
an ionic liquid having a profound impact on antibacterial activity. Hamm et al. (102) 
developed an organosilica sol-gel coating with a high load Ag0/Ag+ NP ionosol in selected 
ionic liquids methyltrioctylammonium bis(trifluoromethylsulfonyl)imide 
([N8881][Tf2N]) or 1-ethyl-3-methylimidazolium bis(trifluoromethyl sulfonyl)imide 
([emim][Tf2N]) and tested their activity against P. aeruginosa.  They observed significant 
antibacterial activity from ionosol-loaded coatings using [N8881][Tf2N] while 
[emim][Tf2N] had no effect. They propose that the octyl chains of the [N8881]+ cation 
diffused through the cell wall and damaged the cytoplasmic membrane, allowing Ag+ ions 
to penetrate the compromised cell and inactivate proteins by reaction with disulfide 
linkages, disrupting the DNA machinery and causing cell death (as shown in figure 2-6).  
[N8881][Tf2N]-based coatings on glass substrates showed 6-log inhibition of bacterial 
growth for 24 hours.  
2.4.2.3 Surface-anchored antimicrobial peptides 
Implant surfaces modified with natural or synthetic antimicrobial peptides (AMPs) 
have also shown promise for infection prevention (66, 103-105). Natural AMPs consist of 
relatively short, amphiphilic amino acid chains (12 to 50 amino acids with >50% 
hydrophobic content) and typically show broad bactericidal activity against both Gram-
negative and Gram-positive bacteria (106). The complexity of their antimicrobial 
mechanisms makes it tough for bacteria to develop AMP resistance, overcoming one of the 
biggest challenges in traditional antibiotics research (105). In one recent report, an AMP 
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called defensin was integrated into a multi-layer alternating cationic/anionic 
polyelectrolyte film (103). These defensin-functionalized films inhibited 98% of E. coli 
D22 growth when positively charged poly(L-lysine) was the outer layer of the film as 
opposed to the negatively charged poly(L-glutamic acid) due to the different adhesive 
interaction behavior of the bacteria. Covalently tethering AMPs to the implant surface is 
particularly interesting since they contain functional groups that may be leveraged for long-
term antimicrobial use (66). Similarly, Sun et al. demonstrated covalent peptide bonding 
to polydopamine (pDA) coated nano-hydroxyapatite (nano-HA) enhanced bioactivity and 
osteogenic differentiation compared with the pristine nano-HA (104). However, AMPs 
have lacked clinical applications due to the continued issues with tissue and cell 
interactions and potential cytotoxicity associated with high concentrations of AMPs (106). 
2.4.2.4 Surface quaternary ammonium salts 
Another possible approach to prevent biomaterial-centered infections is to render 
the biomaterial surface antimicrobial properties by functionalization with quaternary 
ammonium salts (QAS), which are widely known disinfectants (107). Chen et al. (108) 
decorated TiO2 nanotubes with the QAS 3-trimethoxysily-propyldimethyloctadecyl-
ammonium chloride, a positively charged QAS that attracted the relatively negatively 
charged bacteria and provided a 30-day ~93% antibacterial rate against E. coli. Further 
mixing AgNPs in with the QAS-loaded TiO2 nanotubes improved the 30-day antibacterial 
rate to 99.9%. However, QAS surface coatings are cytotoxic to mammalian cells, which 
significantly limit their clinical usefulness.  
2.4.2.5 Nitric Oxide 
The naturally occurring small molecule nitric oxide (NO) is a known strong 
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oxidizer and so has been studied for antibacterial properties.  NO was shown to damage 
the bacterial cell membrane followed by diffusion into the cells, resulting in further 
oxidative damage to vital cell components (109). Holt et al. (110) reported reduced 
bacterial colony counts for up to 48 hours in a rat model using NO-doped xerogel coatings 
on titanium external skeletal fixation pins. They observed that about 50% of the NO was 
released in the first four hours and the entire NO was released within 1-week time. Further 
studies need to performed to investigate the in vivo concentration kinetics of these coatings. 
2.4.3 Coatings that release antimicrobial agents 
An even more “proactive” approach than preventing bacterial adhesion is to kill 
bacterial cells before they come into contact with the implant surface. Controlled, time-
delayed release of drugs from an implant coating allows for administering high drug 
concentrations at and around the implant site and further eliminates reliance on patient 
compliance. Moreover, the overall antibiotic load in the body can remain low, reducing 
effects on healthy tissues and beneficial flora, thereby increasing patient comfort and 
reducing follow-up care costs (55). Mechanisms of controlled release include (1) passive 
transport (i.e. diffusion or convection), (2) solvent-mediated activation and transport, and 
(3) chemical reaction, degradation, or erosion. When discussing individual materials, we 
identify and discuss the mechanisms governing that particular case.  
2.4.3.1 Antibiotic-loaded bone cement 
Antimicrobial cement has been used to prevent periprosthetic infections and 
enhance prosthesis fixation for more than 40 years (111-114). Before arthroplasties that 
promoted osseointegration, polymethylmethacrylate (PMMA) was primarily used to fix 
the arthroplasty to the bone. For preventing or treating infections, most cement consist of 
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PMMA beads (5 to 80 μm diameter) or PMMA-derived matrix, an antibiotic, and a radio-
pacifier, which can be pre-mixed or mixed manually just before coating (48). Their 
function includes dispensing antibiotic, reducing the dead space between the implant and 
bone, and promoting good bone-implant interface adhesion (115).  A review of bone 
cement release mechanisms concluded that initial antibiotic release in the first few hours 
after exposure to fluids was governed by surface phenomena. Presumably, desorption, 
while sustained release over several days was by passive bulk diffusion (48). Some factors 
play a role in determining the actual release rates including the antibiotic type and load, 
cement type, open porosity, and implant surface area available for the cement coating 
(116).   
Elucidating the antimicrobial release kinetics and local spatial distribution is critical 
to understanding the efficacy of such coatings in real clinical applications.  In vitro release 
kinetics of commercially available and manually blended cement were compared by 
Mionla et al (117). They found that the commercially-loaded cement released a higher 
amount of gentamicin than the hand-mixed ones, but no statistically significant difference 
was found in antimicrobial activity.  Mass transport and distribution characteristics have 
been studied in vivo in female rabbit models (118). In this study, the MRI contrast agent 
gadopentetic acid (Gd-DTPA) was used as an indicator and surrogate for gentamicin and 
vancomycin due to its similarity in size and solubility. After 5.5 hours, they observed that 
spatial particle distribution was highly anisotropic and not strictly explained by diffusion.  
In another study performed by Webb et al., in vivo release of gentamicin from PMMA 
cement (Palacos® R-40 gentamicin, Zimmer, Inc., Warsaw, IN) was studied using 
fluorescence polarization immunoassay (FPIA) of urine samples from 35 human patients 
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undergoing THR (119). They observed a bimodal antibiotic release pattern with high initial 
release followed by sustained low-level release. The average release period ranged from 6 
to 14 weeks. However, other studies have shown that antibiotic-loaded cement in TKR had 
no significant effect in reducing the two-year revision surgery rate (120).  
Although antibiotic-loaded cement is efficient, cost-effective means for local 
antimicrobial delivery, there are disadvantages associated with their use. One of the major 
drawbacks is their passive, inefficient release mechanism, which might lead to induction 
of resistant mutant species (121). If used to treat an infection, a second surgery may be 
required to remove the cement after full antibiotic release. Furthermore, the cement is made 
by an exothermic polymerization process that may adversely affect the thermal stability of 
the antibiotics and also limits the choice of drugs that can be used which, in turn, limits the 
organisms that can be treated(121). 
2.4.3.2 Polyhydroxyalkanoates 
Polyhydroxyalkanoates (PHAs) are linear polyesters typically containing a β-
hydroxyalkanoic acid that are produced by bacterial fermentation of sugar and lipids.  They 
can be processed into rod or microcapsule forms to serve as drug carriers (122). An in vivo 
rabbit study by Gürsel et al. showed that drug-loaded PHA rods released drugs for at least 
one week following implantation(123). Turesin and coworkers further showed that adding 
undoped PHA layer atop the antibiotic-loaded PHA rods reduced the release rate and 
demonstrated diffusion-controlled kinetics. Uncoated rods released their antibiotic 
contents in 3 days while the coated rods released 70% of the drug over a period of 2 
weeks(122). Detailed reviews on PHA coatings can be found elsewhere (124). 
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2.4.3.3 Mesoporous materials 
The high surface area and an open porosity of mesoporous materials make them 
suitable vehicles for drug delivery. Mesoporous silica has been found to facilitate drug 
release by diffusion (125). Xia et. al. investigated the drug release properties of several 
gentamicin-loaded mesoporous bioactive glasses (MBG) prepared by two-step acid-
catalyzed self-assembly process. They confirmed that the gentamicin release rate increased 
with increasing pore volume. In vitro comparison of MBG with other bioactive glasses 
showed that gentamicin release from MBG was slower than sol-gel-based bioactive glasses 
and release continued for more than 20 days. 
One major drawback to using MBG is its poor mechanical strength.  Combining 
MBG with more rigid polymers can be used to overcome the poor mechanical strength of 
MBG.  Mabrouk et al. integrated MBG with poly(vinyl acetate) (PVA), which has excellent 
mechanical strength and biocompatibility, and loaded the composite with ciprofloxacin 
(59). The degradation rate of the MBG-PVA composite was significantly slower than PVA 
alone, but an increase in the release rate of ciprofloxacin was observed. The authors 
hypothesized the increase might be a result of bonding affinity between ciprofloxacin and 
the PVA. Interesting reviews on mesoporous materials can be found elsewhere (126). 
2.4.3.4 Hydrogels 
Hydrogels are a class of cross-linked polymers that swell, without dissolving, in the 
presence of water. The swelling characteristic of hydrogels makes them an ideal system for 
controlled drug release from medical implants. Hydrogels can be used with a broad 
spectrum of biomolecules including antibiotics, growth factors, and peptides. One study 
compared the release dynamics of gentamicin between beta tri-calcium phosphate (β-TCP) 
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and gelatin-reinforced β-TCP scaffolds in vitro (127). When immersed in an aqueous 
solution, the gelatin-reinforced β-TCP coating demonstrated zero-order sustained 
antibiotic release profile for 28 days while the unmodified β-TCP coating showed an initial 
bolus release of gentamicin within 10 hours followed by complete release within one day.  
The sustained release observed from gelatin reinforced β-TCP was found to be due to 
gradual hydrogel degradation. An in-vitro antibacterial assay performed on 3- and 7-day 
cultures of S. aureus further demonstrated higher antibacterial properties for gelatin-coated 
β-TCP compared to unmodified β-TCP coatings. Similar results were observed when the 
coatings were analyzed for three weeks in vivo in rodents suffering from osteomyelitis. In 
another study, the authors explored the preparation of polyacrylate-based hydrogel by 
electrochemical polymerization of titanium implants and loaded them with ciprofloxacin 
(128). Subsequent ciprofloxacin release was studied using high-performance liquid 
chromatography (HPLC), and antibacterial efficacy was demonstrated in vitro using 
methicillin-resistant S. aureus (MRSA). Mariner et. al. prepared synthetic hydrogel 
scaffolds that can be used to deliver rhBMP2 to critical-sized bone defect models in rats 
(129). Their hydrogel scaffolds compared favorably to absorbable collagen sponges, 
showing significantly more bone growth over a 6-week observation period. 
2.4.3.5 Drug-eluting degradable coatings 
Biodegradable implant coatings were first introduced by Kulkarni et al. when they 
presented the concept of using poly-lactic acid (PLA) fibers and films for surgical implants 
(130). Since then, biodegradable materials have evolved with accompanied considerably 
greater usage in medical devices. Biodegradable coatings reduce the risks involved with 
the usage of permanent implants and the need for second surgery for implant removal.  
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They are radiolucent and have demonstrated effective controlled drug release (131). 
Another advantage of using biodegradable coatings involves reduced foreign body 
reactions (132). The drug release kinetics can be controlled by altering the polymer 
degradation rate. Some of the conventional biodegradable coatings developed are 
biodegradable polymer coatings, calcium phosphate, chitosan, collagen, and bone grafts. 
1. Polymer coatings 
The first biodegradable polymer coating for implant surface prepared was 
poly(lactic-co-glycolic acid) copolymer (PLGA) coatings loaded with gentamicin for 
fracture fixation plates (133). The antimicrobial effects of the coated implants were tested 
by in vitro bacterial inhibition of S. aureus and were found to be effective for 24 days.  
Gilchrist et al. used a fusidic acid (FA)- and rifampicin (RIF)-loaded PGLA coating for 
biphasic delivery of drugs (134). They used the electrospinning technique to overcome the 
incompatibility of FA and RIF with PLGA. FA/RIF-doped PGLA-coated titanium discs 
were tested in vitro and in vivo against MRSA in a rodent model over a period of 7 days.  
Both in-vitro and in vivo models demonstrated effective inhibition of bacterial growth.   
In addition to PLGA, PLA, hyaluronic acid, poly-D, L-lactide (PDLLA), poly-L-
lactide (PLLA), and polyethylene glycol (PEG) have also been used in the fabrication of 
biodegradable coatings (135). Neut et al. (136) used gentamicin-loaded poly(trimethylene 
carbonate) (PTMC), which inhibits biofilm formation. PTMC is attractive as it can be 
degraded enzymatically without forming acidic degradation products. A gentamicin-
loaded PTMC disc was found to be effective for at least 14 days in vitro (136). Gitelis et 
al. have used antibiotic-impregnated calcium sulfate implants to provide direct local 
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antibiotic delivery. It has been found to be effective for six weeks in animal models (137). 
The anti-adhesive biodegradable multi-layer PVP/PAA and HEP-CHI mentioned above 
also demonstrated antimicrobial activity, with HEP/CHI layers effectively killing S. aureus 
on contact for 2 to 3 weeks (79).   
Although these coatings were efficient at inhibiting bacterial growth there are some 
inherent disadvantages involved in using such systems including low strength and being 
brittle, which are critical material properties for an implant device designed to take repeated 
mechanical loading. An et al. has reviewed in detail pre-clinical in vivo testing of 
bioabsorbable devices (138). Some of the other common biodegradable coatings developed 
are calcium phosphate, chitosan, collagen, and bone grafts. 
2. Calcium phosphate 
Calcium phosphate (CaP) has also been used as a biodegradable carrier for drug 
release.  CaP can be utilized as a cement composition, granules, blocks, ceramics, powders, 
and coatings.  CaP cement is favorable over acrylic (PMMA) bone cement because of their 
inherent porosity and endothermic process, which allows for improved thermal stability of 
heat-sensitive components (139). They can be injected at the site and, therefore, can fit the 
infection site perfectly. As this cement settle in vivo and have chemical and structural 
similarity to natural hydroxyapatites, they have greater reactivity with the host bone.  
Detailed discussion on other useful properties of CaPs can be found in other reviews (139, 
140). Therapeutic application of CaP has been dealt in great detail by Verron et al (141).   
Various synthetic CaP compositions are currently being used such as 
hydroxyapatite (HA), Ca3(PO)4, β-TCP, and mixtures of HA/β-TCP.  HA has been used as 
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a component for implant coatings because of their composition and crystallographic 
structure similarity to the bone. Synthetic HA has excellent biocompatibility and shown to 
improve osseointegration since natural bone is at least 50% carbonated HA by weight (142-
144). Various researchers have used antibiotic- or metal nanoparticle-doped carbonated 
HA coatings to improve antimicrobial efficacy and osseointegration properties(145-148).  
Motoc et. al. deposited active antimicrobial protein and biceramic calcium HA using pulse 
laser deposition on a Ti surface, which demonstrated excellent biocompatibility, human 
cell adhesion, and local antimicrobial efficacy (149). Nanoscale patterned materials have 
also been found to improve specific proteins interactions.   
Zhang et al. made a biomimetic coating combining nanocrystalline HA and helical 
rosette nanotubes, which are very similar to nanostructured collagen (150). They observed 
enhanced osteoblast adhesion when smaller grain sized nanocrystalline HA was used. 
Huang et. al. produced a nano-HA/polyamide66 scaffold coated with berberine-doped 
chitosan that had both excellent antimicrobial properties as well as bone regeneration 
capacity (151). It has been found that nano-HA enhance osteoclast functions and osteoblast 
formation, which is critical since the extent of HA reabsorption by bone followed by 
osteoblast formation decides the fate of the implants (152). Biological evaluation of nano-
HA coatings in vitro revealed that they are active between 24 to 150 hours.  Rauschmanna 
et al. demonstrated better biocompatibility and local antibacterial delivery for highly 
porous resorbable nanocomposites of calcium sulfate and HA in comparison with pure CaP 
(153). The open porosity allowed the uptake of antibiotics (i.e. gentamicin, vancomycin) 
in the materials, which then continued to release for ten days.  
3. Chitosan  
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Chitosan is a linear polysaccharide containing randomly distributed β-(1-4)-linked 
D-glucosamine and N-acetyl-D-glucosamine groups that can be synthesized by treating 
crustacean shells with alkaline sodium hydroxide. Chitosan has proved to be an effective 
drug delivery system as it is non-toxic, biocompatible, has excellent absorbing properties, 
and is biodegradable. Chitosan is degraded easily in the human body when it comes into 
contact with lysozyme to form saccharide and glucosamine (154). Smith and coworker 
(154) loaded daptomycin and vancomycin in dehydrated chitosan films by submerging the 
films in 1mg/ml of antibiotic in phosphate buffered saline (PBS) solution for 1 minute.  
The antibiotic activity of the chitosan films prepared in situ was determined using in vitro 
turbidity assay.  Eluate samples were tested at 48 and 72 hours and found to be effective in 
inhibiting bacterial growth of S. aureus (154). Preparation of the films in situ also resulted 
in significantly decrease coating degradation before implantation. De Giglio and coworkers 
developed a ciprofloxacin-loaded chitosan nanoparticulate coating for Ti implants and 
tested it in vitro against S. aureus and P. aeruginosa (155). The amount of ciprofloxacin 
released was estimated using HPLC and revealed that chitosan-loaded nanoparticles did 
not display any initial burst release profile and the relatively slow release rate (2.8 μg/ml) 
continued after for 120 hours and was effective in inhibiting bacterial growth.  
4. Collagen 
Much research has been done on the use of collagen due to its prevalence in the 
extracellular matrix (ECM). Drug release characteristics depend strongly on the porosity 
and method of preparation (156). Tu et al. produced layered HA and mineralized collagen 
on Ti implants by electrolytic deposition and studied the cytocompatibility and antibiotic 
release kinetics (157). They observed an initial burst release of vancomycin (80-85%) in 
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the first 10 to 16 hours followed by a slow release sustained over four days. Antibacterial 
testing was performed for 16 hours in vitro and showed good antibacterial efficacy. A 
detailed review on efficacy testing in vivo of prophylactic and therapeutic application of 
gentamycin-loaded collagen implants can be found elsewhere (158).  
5.  Bone grafts/Cancellous bone  
Bone grafts, including cancellous bone, are occasionally used for replacing missing 
bone or used to stimulate fracture healing. They have high surface area-to-mass ratio, 
which makes them ideal for use as a drug carrier.  In most cases, they are reabsorbed and 
replaced during the healing process. Zeolites are aluminum silicate minerals which are 
highly porous and can be used as absorbents. In addition to being biocompatible and non-
toxic, zeolites have a significant number of functional groups that can combine with 
various drug molecules by hydrogen bonding. Guo et. al. have used zeolite to fabricate 
bone grafts (159). They demonstrated that the drug loading capacity of zeolite was almost 
three times that of HA while the drug release of gentamicin in phosphate buffer saline 
(PBS) using colorimetric techniques showed that the zeolite exhibited slow and sustained 
release of 62.2% in 6 days. In another study, human demineralized bone matrix (DBM) 
was loaded with gentamicin and used to prevent infection (160). The grafts were able to 
release drugs effectively in vitro for up to 13 days. Meanwhile, there were no adverse 
effects on osteoinductive or osteoconductive nature when tested in vivo in rat ectopic pouch 
models after 28 days. Other studies on antibiotic-loaded bone grafts and DBM can be found 
in detailed reviews elsewhere (161, 162).  
The local application of antimicrobial-eluting agents is a well-known and accepted 
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tool in the treatment of implant-related infections (59). These materials inhibit bacteria 
both locally and remotely from the implant based on the technique used. However, some 
questions arise regarding the by-products of their use, like crystals and acids that are 
formed after degradation that cause inflammation (infection like reaction) (131). The use 
of antibiotics in high doses can also lead to antibiotic-resistant bacteria. Also, these 
coatings tend to have low strength. Further research needs to be done to understand the 
release mechanism of drugs into the body to optimize their usage. 
2.4.4 Coatings that accelerate osteocyte adhesion  
Another way of preventing implant-related infections is by promoting and speeding 
up the adhesion of desired eukaryotic cells so that tissue integration dominates over 
bacterial adhesion in the “race for the surface.”  Layering implants with desired tissue cells 
provides a defense mechanism that can prevent bacterial colonization (163, 164).  Some of 
the techniques to promote osteocyte adhesion are given below. 
2.4.4.1 Incorporation of growth factors 
HA offers several advantages as an implant coating, which includes good bonding 
with the implant and the surrounding tissues. Such properties offer the opportunity for bone 
formation and prevent implant wear and release of metallic particles (165). Along with HA, 
CaP ceramic and octa-CaP coatings have also been explored and found to have desirable 
osteoconductive properties (166). Although these materials provide osteoconductive 
properties, they are themselves not osteoinductive and do not assist in osseointegration.  
Several studies have been conducted to show that the presence of enzymatic and nutritional 
growth factors aids in osteoinduction to achieve improvements in osseointegration (167). 
A bioactivity study in a rat model showed that ~60% of the incorporated growth factors 
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were consumed by the five-week follow-up. Transforming growth factor-β-1 enhances 
bone regenerative properties by stimulating the differentiation of pre-osteoblastic cells 
(168). Bone morphogenic proteins (BMPs) have also been identified as important growth 
factors (169, 170). Reyes et al. observed that coatings comprising type I collagen-mimetic 
peptide glycine-phenylalanine-hydroxyproline-glycine-glutamate-arginine (GFOGER) 
promote osseointegration and cell adhesion by binding to α2β1 integrin (171). 
2.4.4.2 Bioglass 
Bioglass is a surface active member of the bioactive glass family composed of 
sodium oxide, calcium oxide, phosphates, and silicates. Effective bonding and ingrowth of 
bone depend strongly on the bioglass formulation. Naghib et. al. coated steel implants with 
45S5 bioactive glass synthesized by sol-gel technique (172). The bioactive glass showed 
good adhesion to the metal due to its high thermal expansion and bioactivity after 14 days 
in vitro in simulated body fluid. More thorough reviews of sol-gel based biomaterials and 
bioactive glasses, which have been studied extensively, can be found elsewhere (173, 174).  
2.4.4.3 Silicon carbide ceramics 
Biomorphic silicon carbide (SiC) ceramics coated with a bioactive glass layer have 
shown excellent osteoconductive properties (175). SiC possesses excellent mechanical 
properties and low density, which is promising for use with load-bearing implants. The 
SiC-bioactive glass composite resulted in dense apatite layers after 72 hour testing in vitro.  
Dey et al. modified SiC biomaterial with 10-undecenoic acid methyl ester and studied 
CaP/HA formation on the surface for five days after converting the methyl ester to a 
carboxylic acid (176). They observed improved CaP/HA nucleation resulting in well-
defined, highly crystalline multilayers. 
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2.4.4.4 Coating with extracellular bone matrix (ECM) 
Coating implants with ECM components has been found to be an attractive solution 
because it does not lead to foreign body reactions and the ECM can interact with bone cells 
to facilitate bone growth and adhesion (177). Rammelt et al. found enhanced bone growth 
on Ti implants placed in rodent models that had been coated with several ECM 
components: collagen, RGD proteins, and chondroitin sulfate (177). Bernhardt et al. 
performed a similar study in a goat model (178). They observed enhanced bone growth on 
the ECM-coated implant that promoted subsequent implant stabilization.  
Many cases of implant failure are due to loosening and improper osseointegration.  
Coatings that accelerate osteocyte adhesion enhance bone formation and healing.  
However, further research needs to be done in the various immobilization processes and 
their effects on osseointegration rates.  In most cases, the coating manufacture process is 
tedious and yields poor coating-implant anchorage. Also, incorporating different materials 
induces drastically different cellular responses, which need to be studied to identify optimal 
materials for rapid healing and bone formation while ensuring patient safety. 
2.4.5 Coatings with multiple modes of action 
Several researchers have developed composite coatings combining the beneficial 
properties of more than one of the above methods to improve osseointegration and 
antimicrobial efficacy.  Lee et. al. developed a dual drug-eluting heparin-based composite 
coating for Ti substrates (179). The antibiotic gentamicin sulfate and protein bone 
morphogenic protein-2 (BMP-2), which promotes osseointegration, were immobilized in a 
heparin matrix. They observed an initial burst release for one day followed by a sustained 
release of gentamicin and BMP-2 over four weeks. Alkaline phosphatase activity and 
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calcium deposition were also examined, and the composite coating was found to perform 
significantly better than an unmodified heparin coating. Tan et. al tested some composite 
bone cement for biocompatibility and infection inhibition and found that a composite 
quaternion chitosan derivative-loaded PMMA out-performed the PMMA control, chitosan-
loaded PMMA, and gentamicin-loaded cement (180). Macdonald et. al. integrated BMP-2 
growth factors in a multilayered chondroitin sulfate coating (181). Both in-vitro and in vivo 
studies showed bone growth at four and nine weeks, respectively. Cheng et al. used Ag-
impregnated Ti nanotubes fabricated on Ti implants and found that the implants exhibited 
antimicrobial activity for 30 days against S. aureus (MRSA, ATCC43300) in vitro (182). 
The composite is also tested in vivo in rat models and showed satisfactory adhesion and 
integration with the implants. Svensson et. al. performed a similar study where nanoscale 
surface features were utilized in conjunction with noble metal additives (Au, Ag, and Pd) 
for the simultaneous promotion of bony ingrowth and bacterial inhibition at the implant 
interface (183). These coatings inhibited bacterial infection in vitro while osseointegration 
was observed in vivo using a rat model. Kazemzadeh-Narbat et. al. used electrolytic 
deposition of a thin CaP layer on Ti substrate to act as a carrier for antimicrobial peptides 
(106). Analysis of the coatings was performed in vitro against both gram-positive S. aureus 
and gram-negative P. aeruginosa. The coatings were effective in killing both strains of 
bacteria in less than 150 minutes. Bone growth analysis was done by implanting the 
coatings in rabbit models. Backscattered electron microscopy was done to confirm the 
formation and growth of bone, which was considerably higher on an uncoated Ti substrate. 
Another effort to utilize multiple modes involved simultaneous testing of the zeolite 
anti-adhesive property derived from its super-hydrophilicity and ion exchange property for 
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hosting and regulating the release of Ag0/Ag+ antimicrobials (184). Wang et al. 
demonstrated in vitro that bacterial adhesion and proliferation of S. aureus was 
significantly inhibited using silver-doped zeolite coatings, evaluated both at the implant 
surface and in the surrounding culture medium.  The antibacterial and anti-adhesive zeolite 
coatings show great potential for application in orthopedic implants and general wound 
care (184, 185). 
Coatings with multiple modes of action prove to be a promising technique for 
preventing infection as well as enabling bone growth. Despite their multifaceted utilities, 
several questions need to be addressed. Firstly, the performance of these implants may be 
hampered by protein attachment to the surface blocking active sites or preventing diffusion 
of antimicrobial agents. The success of these implants depends on the host tissue response, 
and they are in vivo performance in overcoming adverse reactions. Secondly, the ease of 
manufacture and robustness of these coatings need to be considered. Further research needs 
to be done to prevent loss in functionality before osseointegration and implant stabilization 
is complete. 
Table 2.2: A summary of the various coatings and surface modifications imparting 
antimicrobial activity to orthopedic implants and their duration of efficacy. 
Mode of action  Type of antimicrobial coating Duration of 
antimicrobial 
efficacy 
Prevent bacterial  
adhesion via physical 
(a) Sacrificial surfaces (74, 79) 9-10 weeks (in 
vitro) 
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effects 
 
(b) Adhesion-resistant coatings (82, 91-93) 
(i) Unstructured polymer coatings 
(ii) Polymer brushes 
(iii) Diamond-like carbon coatings 
90 days (in 
vitro) 
Kill adherent bacteria 
 
(a) Photoactive coatings (96) Two days (in 
vitro) 
(b) Metal impregnated surfaces (99-101) 21 days (in 
vitro) 
(c) Surface-anchored antimicrobial 
peptides (66, 103, 106) 
Seven days (in 
vivo) 
(d) Surface quaternary ammonium salts 
(108) 
30 days (in 
vitro) 
(e) Nitric oxide (110) 48 hours (rat 
model) 
Release antimicrobial 
agents to surrounding 
regions 
 
(a) Antibiotic-loaded bone cement (117-
120)  
6-14 weeks (in 
vivo) 
(b) Polyhydroxyalkanoates (122, 123) 
 
Up to two 
weeks (in 
vitro) and up to 
six weeks (in 
vivo) 
(c) Mesoporous materials (59, 125) Up to 20 days 
(in vitro) 
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(d) Hydrogels (127-129) Up to 28 days 
(in vitro) 
3-6 weeks (in 
vivo) 
(e) Drug-eluting degradable coatings (79, 
133, 134, 136, 137, 151-155, 157, 159, 
160)  
i. Polymer coatings 
ii. Calcium phosphate 
iii. Chitosan 
iv. Collagen 
v. Bone grafts/ Cancellous bone 
2-3 weeks (in 
vitro) 
Up to six 
weeks (in vivo) 
Accelerate adherence 
of desired cells 
 
(a) Incorporation of growth factors (167, 
169-171) 
4-5 weeks (in 
vivo) 
(b) Bioglass (172) 14 days (in 
vitro) 
(c) Silicon carbide ceramics (175, 176)  3-5 days (in 
vitro) 
(d) Coatings with ECM (177, 178) 4-12 weeks (in 
vivo) 
Coatings with multiple 
modes of action 
Coatings with multiple ways of action 
(106, 179-185) 
Up to four 
weeks (in 
vitro) 
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4-9 weeks (in 
vivo) 
 
2.5 Conclusions 
Numerous approaches toward realizing robust, inexpensive antibacterial coatings 
have been described. Varying degrees of success at preventing the colonization of implant 
surfaces by bacteria have been achieved. However, bacteria are not only hardy but are 
continuously introduced and re-introduced into the bloodstream by daily activities (e.g. 
brushing teeth, scrapes, minor cuts) and by surgical procedures such as catheter insertion 
and gastrointestinal surgery. Under normal circumstances, the microorganisms that enter 
the bloodstream (i.e. transient bacteremia) are neutralized by the body’s immune system. 
However, orthopedic implant surfaces provide a convenient “hideout” for bacteria and 
transient bacteria reaching the implant surface can develop into full-blown infections even 
months after implantation. Thus, it is highly desirable that coatings retain their 
antimicrobial activity for as long as possible. Methods/coatings employing a combination 
of the approaches described above may be more effective antimicrobials as they carry some 
redundant activity that is not easily bypassed. Also likely to prove effective are ‘smart’ 
materials: those that either release their active antimicrobial agents in a controlled manner 
or only in response to the presence of microbes. However, efficient reduction in 
microorganism loads alone will not ensure wide acceptance or commercial success of the 
special coating. For the latter, the coating will not only have to meet various mechanical 
criteria (e.g. bond strength of the implant coating interface, resistance to repeated 
mechanical loading) and biological constraints (e.g. demonstrate non-toxicity to humans, 
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promote osseointegration) but will also have to be cost-effective when manufactured in 
bulk. As all current coatings fail at one of these three criteria, the next-generation 
antimicrobial coating to be used in virtually all implants remains an elusive target.        
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CHAPTER 3 
3 FOAMING BETADINE SPRAY AS A POTENTIAL AGENT FOR NON-LABOR-
INTENSIVE PREOPERATIVE SURGICAL SITE PREPARATION 
The material presented in this chapter was reviewed and published as “Foaming Betadine 
Spray as a potential agent for non-labor-intensive preoperative surgical site 
preparation” 
Roli Kargupta,, Garret J Hull, Kyle D Rood, James Galloway, Clinton F Matthews, Paul S 
Dale and Shramik Sengupta 
Annals of clinical microbiology and antimicrobials, 2015. 14(1): p. 20. 
 
The Centers for Disease Control and Prevention’s (CDC) National Healthcare 
Safety Network (NHSN) report published in 2009 shows that there were about 16,000 cases 
of surgical site infection (SSI) following ~ 850,000 operative procedures making SSI one 
of the most predominant infections amongst nosocomial infections. Preoperative skin 
preparation is a standard procedure utilized to prevent SSIs thereby improving patient 
outcomes and controlling associated healthcare costs. Multiple techniques/ products have 
been used for pre-operative skin preparation, like 2-step scrubbing and painting, 2-step 
scrubbing and drying, and 1 step painting with a drying time. However, currently used 
products require strict, time-consuming and labor-intensive protocols that involve repeated 
mechanical scrubbing. It can be speculated that a product requiring a simpler protocol will 
increase compliance, thus promoting a reduction in SSIs. Hence, the antimicrobial efficacy 
of a spray-on foaming formulation containing Betadine (povidone-iodine aerosol foam) 
that can be administered with minimum effort is compared to that of an existing 
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formulation or technique (Wet Skin Scrub). 
 In vitro antimicrobial activities of (a) 5% Betadine delivered in aerosolized foam, 
(b)  Wet Skin Scrub Prep Tray and (c) liquid Betadine are tested against three clinically 
representative microorganisms (S. aureus, S. epidermis, and P. aeruginosa,) on two 
surfaces (agar-gel on petri-dish and porcine skin). The log reduction/growth of the bacteria 
in each case is noted, and ANOVA statistical analysis is used to establish the effectiveness 
of the antimicrobial agents, and compare their relative efficacies.  
With agar gel as the substrate, no growth of bacteria is observed for all the three 
formulations. With porcine skin as the substrate, the spray-on foam’s performance was not 
statistically different from that of the Wet Skin Scrub Prep technique for the 
microorganisms tested. 
The povidone-iodine aerosolized foam could potentially serve as a non-labor 
intensive antimicrobial agent for surgical site preparation.  
3.1 Background 
Surgical site infection (SSI) is one of the major concerns associated with surgery 
(13, 186). SSIs can lead to severe complications, and also to patient mortality in extreme 
cases (16). A 2009 estimate of the annual direct medical costs of Hospital Acquired 
Infections (HAI) by the Centers for Disease Control and Prevention (CDC) estimated the 
number of SSIs in the USA to be >290,000 per year, with an estimated cost of resulting 
inpatient services of up to $ 10 Billion (8). A reduction in the incidences of SSI would thus 
significantly improve patient wellbeing with a significant decrease in healthcare expenses 
(12, 187).   
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Colonizing microorganisms often cause SSI. Microorganisms present in the skin 
and the operation room can readily enter a patient’s body through the site of an incision 
(15). Transient bacteria present on the skin can and do cause SSIs, and reducing their 
number is of vital importance. This is achieved using a combination of processes: 
sterilization of the operating room, cleaning, showering and de-hairing of the surgical site, 
and scrubbing the surgical site with antimicrobial agents (15, 188). 
Commonly used antimicrobial agents are alcohol, iodine, chlorhexidine and 
povidone-iodine solution (PVP-I) among others (16). They can be administered in the form 
of liquids and solutions (13). The choice of antimicrobial agent and the technique of 
preoperative skin preparation to be used depends on various factors like surgeon’s 
familiarity with the technique, cost, efficacy of the agent used, ease of use, surgical site 
and possible bacteria present at the site (189). There are several techniques like 1-step paint 
and dry method (taking about 3 minutes) or only scrub and dry techniques (taking greater 
than 5 minutes) or scrub-paint technique (taking about 5 minutes) (190-193). We selected 
the wet skin scrub prep technique as it is a commonly used technique in the operating room 
and the technique of choice for some clinicians at our institution. Drawbacks of the current 
protocols of surgical site preparation techniques are; they are laborious, time-consuming, 
expensive and often require the user to follow certain strict protocols (16, 188, 194). It is 
speculated that a product sprayed directly at and near the surgical site would be able to 
overcome these disadvantages, resulting in a reduction in time, effort, and personnel 
needed for surgical site preparation, and hence cost incurred.  
While there are multiple products available for surgical site preparation (with 
varying, but broadly comparable efficacies), a common preoperative surgical site 
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preparation technique involves a 5-minute scrub with povidone-iodine detergent (17). If 
the 5-minute scrub is replaced with a spray-on protocol taking 2 minutes, it could result in 
saving 3 minutes during every surgical procedure. Given average operating room charges 
of $62/minute, this three-minute reduction in surgical site preparation will lead to savings 
of $186/case if the cost of the spray-on product is similar to the existing technique (195). 
This increased efficacy would result in saving $0.93 million a year and also generate 
15,000 minutes of extra procedure time for hospitals that annually perform about 5000 
procedures. The time saved can be rightfully utilized for additional procedures. Also, SSIs 
have been estimated to increase hospital expenses per admission by $ 20,842 (196). So the 
reduction of both extra procedure time and incidence of SSI can lead to a decrease in the 
financial burden of the patient. 
It is estimated that a large percentage of surgical site infections (up to 60%) can be 
prevented following proper SSP techniques (197). Therefore, any preoperative skin 
cleaning technique whose efficacy is at least equal to that of the existing methods, but 
which is less dependent on user skill is likely to improve overall outcomes.  
3.2 Materials and Methods 
3.2.1 Overview 
The bactericidal efficacy of our spray-on formulation (povidone-iodine aerosol 
foam), is compared to that of the traditional sponge-based application method using the 
methodology schematically depicted in Figure 3-1. Details regarding individual steps in 
the protocol are described below. Standard 0.5 McFarland bacterial suspensions are spread 
on two different substrates: sterile nutrient agar and sterilized porcine skin. The substrates 
are incubated for an hour to allow sufficient time for the bacteria to adhere to the substrates. 
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Post incubation, the surfaces are exposed to the various preoperative skin preparation 
techniques: povidone-iodine aerosol foam, wet skin scrub prep tray, flood coverage with 
liquid Betadine (positive control) and flood coverage with Phosphate buffer saline (PBS) 
or no treatment (negative control). Post-exposure, the substrates are again incubated for 24 
hours. After 24 hours, the number of surviving bacteria is estimated using colony counts, 
to estimate the bactericidal efficacy of the various techniques. 48 hours incubation of the 
plates is also done to validate if the bacteria are killed during the process or are merely 
injured and could grow if proper nutrients are provided to it (198).  
Figure 3-1 Schematic of the method of testing the bactericidal efficacy.  This 
schematic details the methodology of screening the bactericidal efficacy using 
Povidone-iodine aerosol foam, sponge based applicator, and flood coverage with 
liquid Betadine.  
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3.2.2 Bacterial cell culture 
The micro-organisms used in the study are gram-positive bacteria Staphylococcus 
aureus ATCC 29213 and Staphylococcus epidermis ATCC 12228 and gram-negative 
bacteria Pseudomonas aeruginosa ATCC 27853. The bacterial strains were chosen for the 
study contribute to about 42% of SSI (15). The strains are sub-cultured in Tryptic Soy 
Broth (TSB) and incubated for 20-24 hours at 37°C to obtain log-culture. Following which 
standard 0.5 McFarland bacterial suspension is prepared in TSB for use in the study using 
standard protocols (199). 
3.2.3 Selection of substrates 
The antimicrobial efficacy of the agents used for preoperative skin preparation is 
tested in vitro using both agar plates as well as porcine skin. Tryptic Soy Agar (TSA) plates 
are used for culturing the bacteria. 
Porcine skin is chosen for its close resemblance to human skin, and has previously 
also been used for studying the effect of chemicals on human skin (200, 201). Porcine skin 
purchased from local grocery shops is cleaned, de-haired and cut into one square inch 
pieces and sterilized, before use. The sterilization protocol, described in detail elsewhere 
(202) involved treating the skin pieces with an aqueous solution of 1M sodium chloride 
and 0.1% (v/v) peracetic acid with continuous stirring of the solution at 225rpm for 30mins.  
It is followed by two times rinsing in PBS for 24hours each time by continuous stirring at 
225rpm (202, 203). 
3.2.4  Selection of antimicrobial agents for testing 
Liquid, 5% Betadine, is used for flood coverage of the substrates. Preoperative wet 
skin scrub prep kit containing sponge applicators are used for the study with the applicators 
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wetted with 5% Betadine before scrubbing. The aerosolized foam of povidone-iodine, 5% 
Betadine is used. The product is designed to be sprayed on the surgical site from a distance 
of 4-8 inches, resulting in the site being covered with foam.  The propellant gasses present 
in the aerosol foam canister mix with anti-microbial agents like povidone and iodine to 
produce a layer of foam. It requires less manual labor, unlike scrubbing or painting. After 
predetermined contact time, the foam can be removed from the site with a sterile cloth thus 
making the site ready to be operated.  
Also, to prove that there is no mechanical washing away of the bacteria on being 
flooded with 5% Betadine, the experiment was repeated with 1X PBS instead of 5% 
Betadine. 
3.2.5 Evaluation of bactericidal activity 
For each bacterial culture, both agar plates, and porcine skin is used. Five agar 
plates are utilized for each case: control, flood coverage by 5% Betadine, sponge-based 
applicator and povidone-iodine aerosolized foam (our product). Similarly, for porcine skin, 
a group of 5 one-inch square skin pieces is used for each case, control, flood coverage with 
5% Betadine, sponge based applicator, and our product. 
Each bacterial culture is diluted to ~1*104 CFU/ml and 100µl is of the diluted 
bacteria is used for inoculation. It is thus expected that there will be ~103 CFU on agar 
plates and porcine skin before disinfection. Post-inoculation, the agar plates, and the 
porcine skin are allowed to incubate at room temperature for 1 hour. After this incubation 
time, the control samples of agar plates are allowed to incubate at 37°C for 24 hours. The 
imprint of the control samples of the porcine skin is taken on agar plates with the plates 
being incubated at 37°C for 24 hours. It may be noted that samples were incubated for 48 
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hours in the hope of detecting bacteria that were only injured, but not killed by the 
disinfecting techniques (198). 
The steps involved in treating the agar plates and the porcine skin with flood 
coverage of Betadine, aerosolized foam and sponge based applicator are depicted in 
Figures 3-2 and 3-3, respectively. 
For agar plates and skin pieces serving as a substrate for 5% Betadine about 5-10ml 
of liquid 5% Betadine, is poured on the surface. This ensures flooding and complete 
coverage of the entire surface of the agar plates/porcine skin with 5% Betadine. After 2 
Figure 3-2 Steps involved in evaluating bactericidal activity on nutrient agar 
plates. Steps involved in treating the agar plates with flood coverage of Betadine 
aerosolized foam and sponge based applicator and evaluating its bactericidal 
activity. 
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minutes of contact, the agar plates are flipped upside down to remove excess solution. In 
the case of porcine skin, the skin is taken out and shaken well to remove excess solution 
and imprinted on agar plates.  
For groups of agar plates and skin pieces being used for our product, the aerosolized 
foam is sprayed on the surface. After two minutes of contact time, the aerosolized foam is 
removed from the surface and in the case of porcine skin the imprints of the skin are taken 
on agar plates. Similarly, for the agar plates and porcine skin pieces used for sponge based 
applicator, the sponge post wetting with liquid 5% Betadine is gently rubbed on the 
Figure 3-3 Steps involved in assessing bactericidal activity on porcine skin. Steps 
involved in treating the porcine skin with flood coverage of Betadine aerosolized foam 
and sponge based applicator and evaluating its bactericidal activity 
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inoculated surface in natural motion. The porcine skin is held firmly with a sterilized 
forceps to enable researchers to scrub the surface thoroughly, like the real world situation. 
Damaged plates resulting from scrubbing were discarded. Post surface rubbing with the 
wet sponge for two minutes; a dry sponge is used to remove the excess liquid. In the case 
of the porcine skin, they are taken out and imprinted on an agar plate.  
3.2.6 Statistical analysis  
Statistical analysis was performed in Microsoft Excel using analysis of variance 
(ANOVA) single factor to establish the efficacy of the antimicrobial agents used.  A 
measure of the significance of differences is the p-value. The p-value thus provides a more 
intuitive feel of the degree of difference between the two quantities being compared. For 
our case, the null hypothesis is that the number of surviving bacteria (colonies) remaining 
is equal for the two processes that we compare, namely, aerosolized foam and sponge based 
applicator. 
3.3 Results 
Figure 3-4 shows the number of live bacteria remaining on the surface of the agar 
plate after addition of 100µl suspension with 104 CFU of bacteria/ml on a TSA petri-dish 
and subsequent treatment with the disinfection protocols of interest. For the control (no 
disinfectant applied), this number starts at 1000 CFU and increases over 24 and 48 hours. 
More importantly, all the disinfection protocols, like povidone-iodine the aerosol foam, 
sponge based applicator, and flood coverage with liquid 5% Betadine (positive control) are 
equally effective for all three bacterial species the tested (S. aureus, P. aeruginosa, and S. 
epidermis). All bacteria are eliminated (no colonies are seen after 24 or 48 hrs of 
incubation, post-treatment).  
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 Figure 3-5 show the results of the tests conducted on porcine skin subjected to the 
same preoperative skin preparation (disinfection) techniques tested against the same set of 
bacteria. In this case, different disinfection protocols have different outcomes. It is 
noteworthy that (as expected for a positive control), the flood coverage with liquid 
Betadine can eliminate all bacteria present in this case as well. For the applicator sponge 
Figure 3-4 Viable bacterial count for different bacteria tested on agar 
plates. Number of live bacteria (CFU/100µL) observed on agar plate after 
24 hours and 48 hours for negative control (no treatment done), application 
of aerosolized foam, application of sponge based applicator and positive 
control (application of 5% Betadine) for S. aureus (top left)[n=4], P. 
aeruginosa (top right)[n=5] and S. epidermis (bottom left)[n=5]. 
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(currently used method for pre-operative skin disinfection), none of the bacteria tested were 
eliminated, although in 2 of the 3 cases (for S. aureus and P. aeruginosa) all were at least 
injured (no colonies seen at 24 hrs). With the foaming betadine suspension (new product 
Figure 3-5 Viable bacterial count for different bacteria tested on porcine skin. 
Number of live bacteria (CFU/100µL) observed on porcine skin after 24 hours and 
48 hours for negative control (no treatment done), application of aerosolized foam, 
application of sponge based applicator and positive control (application of 5% 
Betadine) for S. aureus (top left)[n=4],  P. aeruginosa (top right)[n=5] and S. 
epidermis ((bottom left)[n=5] 
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being investigated), the results obtained did not show statistically significant difference 
when compared to the sponge applicator for all the bacteria tested. S. aureus was 
eliminated, and the number of colonies observed for the two other bacteria was lesser than 
the corresponding number for the sponge applicator at both 24 and 48 hrs. The p-values 
obtained when comparing similar readings (same bacteria, same duration of incubation) 
are shown in Table 3.1.     
When the experiment was repeated by flood coverage of the plates with 1X PBS, it 
was observed that the plates showed bacterial growth similar to that of the control samples 
for both the substrates. This clearly indicated that there was no mechanical washing of the 
bacteria when flooded with Betadine but antimicrobial effects arose due to the chemical 
activity of 5% Betadine.  
Table 3.1. p-values calculated using null hypothesis for all applications. List of p-
values, as calculated for the null hypothesis that the two disinfection protocols (aerosolized 
foam and sponge based applicator) are equally effective. (n = 4 for S. aureus; n=5 for S. 
epidermis and P. aeruginosa). 
 
 
 
 
 
 
Bacterial 
species 
Observation time 
period 
Porcine skin 
S. aureus 
24 hrs - 
48 hrs 0.1682 
P. aeruginosa 
24 hrs 0.4876 
48 hrs 0.3486 
S. Epidermis 
24 hrs 0.4929 
48 hrs 0.2819 
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3.4 Discussion 
For agar plates as a substrate, the aerosolized foam, like the other existing methods 
of application, has a very strong bactericidal effect, as observed from the lack of colonies 
even after 48 hours for all the disinfection methods examined. Given that these plates 
provide a smooth surface for the antimicrobial agents to come into contact with the 
bacteria, it can be considered as an ideal case.  
Porcine skin can be regarded as a more realistic model for studying human skin in-
vitro. Here, the bactericidal effect of the agents tested is mitigated by pores, folds and other 
structures in the skin that prevent the antimicrobial agents from sustained contact with the 
bacteria. Though all agents show approximately 2-log reductions in bacterial number, the 
tested foam did not have any statistically significant difference in efficacy when compared 
with the other agent/method tested as seen from the statistical analysis. It may be noted that 
none of the current surgical site preparation practices can completely sterilize skin.  
Further, this is a preliminary study that merely looks at the efficacy of the foam 
against three bacterial species in-vitro, and it only suggests that the foam can be used for 
the surgical site preparation. Additional studies on live animals and humans in a “real-
world” setting may be needed before one can accurately establish how effective it is 
compared to other formulations/ methods available in the market, and whether there are 
any conditions under which it may not be as effective.      
3.5 Conclusion 
This study shows that using a new delivery system (aerosolized foam) for an 
established antiseptic (Betadine) achieved bactericidal results comparable to a traditional 
system that is currently used when tested in-vitro on both agar plates and porcine skin.  
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Given the limitations of this preliminary study, further studies venturing into 
clinical trials will be needed to obtain substantial evidence for SSI prevention using this 
product. Such studies will also explore how the aerosolized foam compares with many 
other kinds of surgical skin preparation products/techniques and whether the anticipated 
advantages of using the aerosolized foam (lower “error” rate due to its ease of use, and 
saving health care costs by virtue of requiring less time compared to the standard method) 
can be realized in a “real world” clinical setting.  
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CHAPTER 4 
4 MICROCHANNEL ELECTRICAL IMPEDANCE SPECTROSCOPY 
The impedance of a system is measured by applying an alternating voltage to the 
system and then measuring the alternating current through the system. Any chemical 
system can be represented as an equivalent circuit composed of resistors, capacitors, and 
inductors. This equivalent circuit describes the “complex resistance” or Impedance that the 
alternating current encounters when passing through the system (204). Electrical 
impedance is a non-destructive and non-invasive technique.  
Sengupta et. al used electrical impedance spectroscopy (EIS) to detect the presence 
of living and viable bacteria in a suspension (205). Bacteria are prokaryotes and are 
surrounded by a cell membrane that encloses the contents of a cell. That is, the membrane 
of the cell acts as an interface that separates the cell interiors from the external broth media. 
Bacterial cells can store charges (capacitance) when exposed to an alternating field due to 
the presence of cell membrane (206). These cells, therefore, act as capacitors and contribute 
towards the capacitance of the suspension.  
A capacitor is an electrical component that can store electrical energy (store 
charges) in an electrical field. The most commonly used capacitor involves two electrical 
conductor plates separated by an insulating material. On application of an electric field, the 
positive charges tend to collect on one plate while the negative charges collect on the other 
plate resulting in the formation of an electric field. Capacitance is measured as 
𝐶 =
Q
V
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Where,  
C = Capacitance (Farads) 
Q = electric charge on each conductor (Coulombs) 
V = potential difference between the plates (Volts) 
For parallel plate systems, where A gives the area of the plates and a distance of d separates 
the plates, the capacitance of the system is given by 
C =
𝜀𝐴
d
 
Where, 
ε = permittivity = ε0εr  
ε0 = permittivity of vacuum 
εr = relative permittivity 
Bacterial cells act as dielectric particles and have both capacitive and resistive 
properties. However, if the cell is dead or unviable, the cell membrane of the bacteria is 
disrupted, and it loses its ability to store charges (206). Hence, any change in the number 
of cells in the suspension can be easily monitored by EIS. Thus, EIS technique can be used 
to distinguish the bacterial capacitance from a dead or unviable and alive or viable cell.  
 The presence of a microorganism in a suspension affects the impedance of the broth 
in two ways. Firstly, there may be a change in capacitance of the media due to the 
metabolites produced by the bacteria during its growth like carbon dioxide and organic 
acids; secondly, the charge storing capacity of a cell itself adds to the capacitance of the 
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media (205, 207). In a bacterial solution, other parasitic capacitors like the interfacial 
double layer capacitor can overwhelm the capacitance signal obtained from the bacterial 
cells in the bulk capacitance. However, prior work has been shown that by application of 
microfluidics and using a very thin capillary, the time constant for impedance effects of the 
bacteria can be significantly enhanced and recorded (205).  
 The microfluidic cassette employed by us has long thin capillary channels having 
a radius of 1mm with two gold electrodes inserted into the channel at a distance of 1cm (as 
shown in figure 4-1(a)). The bacteria suspension is inserted into the channel and an AC 
voltage across a frequency ranging from 1 kHz to 100 MHz is applied across the bacterial 
Figure 4-1 (a) Microfluidic channel with gold electrodes inserted at 1cm interval 
used for EIS analysis of bacterial solution. (b) Electrical circuit model to 
represent the presence of bacteria between two electrodes when a voltage is 
applied across them (205). 
(a) 
 
(b) 
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suspension captured in the channel. An Agilent 4294A Impedance Analyzer is used to 
detect the impedance change of the system. A sinusoidal potential is applied to the system 
and when expressed as a function of time, 
𝑉 = 𝑉0 sin (𝜔𝑡) 
Where, 
V0 = amplitude of the potential applied 
ω = radial frequency  
t = time 
The response current generated is also in sinusoidal form but shifted in phase and can be 
denoted by  
𝐼 = 𝐼0 sin (𝜔𝑡 +  𝛷) 
Where,  
I0 = amplitude of the current 
Φ = phase shift 
The impedance of the system, thus, is dependent on the applied frequency and can be 
expressed analogously to the Ohm’s law as  
 Z=
𝑉0sin (𝜔𝑡)
𝐼0sin(𝜔𝑡+𝛷)
 
Where, 
Z= impedance of the system, 
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V0 sin (ωt) = Voltage applied as a function of time 
I0 sin (ωt + Φ) = Response current as a function of time 
ω = radial frequency 
Φ = phase shift 
The impedance can also be expressed as a complex number using Euler's relationship, 
𝑍(𝜔) = 𝑍0 (cosΦ + jsinΦ) 
The real part denotes the resistance while the imaginary part denotes the reactance of the 
system. 
As the bacterial number changes over time, there is a significant shift in the 
impedance of the suspension. The use of long and narrow microfluidic channels results in 
increasing the bulk resistance of the system. As seen in figure 4-1b, the reactance of the 
system is obtained by multiplying the bulk capacitance with the bulk resistance. Hence, 
any change in the reactance value gets magnified. In addition, operating in high frequencies 
>1MHz, further magnifies the effect. This system can also be applied to blood samples as 
the number of blood cells in a sample do not change with time, and hence any capacitive 
change in the system can be attributed to the change in the bacterial population in the 
suspension.  
 The circuit diagram of the device architecture is shown in figure 4-1(b). In the 
circuit, as illustrated in figure 4-1(b), the resistance due to the charge transfer is negligible 
and neglected as we are working with non-faradaic reactions. The screening effects arising 
from the electrode-solution interactions are accounted by the electrode interference 
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capacitances (Ce), while the charges stored by the bacteria is denoted by the bulk 
capacitance (Cb).  Thus the equivalent circuit of our system is 
 
The number of bacteria present in the system modifies the bulk capacitance of the media. 
Hence any changes in the bacterial number is reflected by a concomitant change in the 
impedance of the system. 
It is worthwhile to note that for all practical purposes, the equivalent circuit often 
has components like an inductor, Le which accounts for the noise in the overall circuit. 
Resistance, Re accounts for the resistance of the electrode due to the electrodes and 
connectors present. Rb is the resistance due to the media and bacterial cells. The bacterial 
Cb is overshadowed by Ce, the parasitic capacitance of the electrical double layer at the 
electrodes. Ce is a function of the ionic strength of the suspension only. However, using an 
optimized geometry of the capillary channel the relaxation time constant of the bulk, RbCb, 
becomes comparable to that of the interface, ReCe (205). Suitable modifications of the 
electrode geometry and the microfluidic architecture like a long and narrow channel and 
use of high frequencies allow us to detect any changes in Cb.  
This allowed the researchers to study the changes in measured impedance chiefly 
due to the change in the bulk capacitance. The change in the bulk capacitance reflects the 
change in the number of the bacteria. It is well known that bacteria in a solution do not 
behave as ideal capacitors and hence the capacitance of the bacteria is better represented 
by constant phase element (CPE) in the equivalent circuit (3, 204). This non-ideal behavior 
73 
 
of cells results in semicircles with centers at the x-axis to be slightly depressed. Hence a 
circuit element CPE is introduced to account for the non-homogeneity of the system. The 
impedance of CPE is a combination of two values – CPE-T measured in Fs(α-1) and CPE-P 
(phase component) which has numerical values less than 1. Mathematically, the impedance 
of a CPE is given by, 
ZCPE = 
1
(𝑗𝜔)𝛼𝐶
 
Where, 
C = capacitance 
α = values less than 1 
It is worthwhile to note that here, the phase component of the bulk is strictly a 
measure of the type of bacteria and the media. It is independent of the bacterial 
concentration as has been shown elsewhere (3). On the other hand, bulk CPE-T is a 
measure of the concentration of bacteria in the solution. For most bacterial and media 
combination the bulk CPE-P is found to deviate slightly (approx. 0.95-0.97) from an ideal 
capacitor (CPE-P =1). Hence for all purposes, we use the unit Farad to represent the bulk 
CPE-T even though ideally the units should be Farad x second(α-1) (3). For our system, the 
impedance response tends to be a capacitor at higher frequencies [Z ~ (ωC )-1] while it 
tends to be a resistor at lower frequencies [Z ~ R]. 
The experimentally obtained data is fit on a circuit built using the various electrical 
parameters, known as the equivalent circuit model to analyze and interpret the impedance 
data. It is worthwhile to note that an increase in bacterial growth leads to a concomitant 
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increase in impedance while a decrease in the impedance is recorded as a measure of the 
death of cells. On modeling, the observed impedance data to an equivalent electrical model, 
the increase in the impedance of the solution appears as an increase in bulk capacitance.  A 
commercial software called Z-view® is used to fit the equivalent circuit models with the 
impedance values obtained from the EIS of the bacterial culture as shown in figure 4-2. 
This allows us to find the values of individual parameters in the circuit, Ce, Re, Le, Rb and 
Cb, as shown in figure 4.2. A plot of Cb-T with time denotes the change in capacitance of 
the bacterial population over time.  
Here, we have applied the same principles to acid-fast bacteria like Mycobacterium 
bovis BCG (M. bovis BCG) and Mycobacterium smegmatis (M. smegmatis) to analyze their 
Figure 4-2 Z-view® software used for EIS data fitting. Inset (Equivalent circuit 
model) 
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time-to-detection. The automated culture-based systems using impedance technology 
measures the discernable change in impedance chiefly by the change in the resistance of 
the growth media/conductivity of the double layer resulting from the generation of 
metabolites. However, our technique is not based on the changes caused by the bacterial 
metabolism but by directly measuring the number of bacteria present in the media. Some 
examples of currently available automated culture-based systems that are based on 
impedance changes occurring at the double layer involve the Bactometer (Bio Merieux, 
Nuertingen, Germany), the Malthus systems (Malthus Instruments Ltd., Crawley, UK), 
rapid automated bacterial impedance technique (RABIT) (Don Whitley Scientific Ltd., 
Shipley, UK), and BacTrac (Sy-Lab, Purkersdorf, Austria) for blood culture purposes 
(207). Till date, no culture based systems using impedance spectroscopy exists that uses 
just change of impedance resulting from the change in the bacterial concentration in the 
media to detect the presence or absence of bacteria in a system. 
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CHAPTER 5 
5 MYCOBACTERIA 
5.1 Background 
 The genus Mycobacterium mostly appears as saprophytic inhabitants. However, it 
also includes several disease-causing pathogens that can cause diseases in humans and 
animals. Most of them are aerobic, non-spore forming and non-motile bacteria that can be 
found in air, water, and soil. The manifestation of these pathogens may be in pulmonary, 
skin or soft tissue lesions and some of the serious, chronic diseases which result from 
mycobacteria are tuberculosis, leprosy (208). Preventing the transmission of mycobacteria 
is difficult as they are resistant to drying, alkali treatment, frozen section preparation and 
many chemicals (26, 209). Also, they have been found to be resistant to several antibiotics 
and chemotherapeutic agents (209). The drug resistance in mycobacteria is attributed to its 
hydrophobic cell envelope as well as due to the presence of hydrolytic or drug modifying 
enzymes (210). 
 Tuberculosis (TB), is the second deadliest disease amongst infectious diseases, 
caused by Mycobacterium tuberculosis. Even with all advances and better detection 
techniques, the detection rate is very low. This is so as in most cases, a patient afflicted 
with TB is asymptomatic and noninfectious. This compounded by the fact that M. 
tuberculosis has a long generation time, extended dormancy periods, complex cell 
envelope and intracellular pathogenesis (210).  
 Based on their generation times mycobacteria are divided into slow and rapid 
grower species. Species that need more than seven days to form colonies on solid media 
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under optimum conditions are known as slow growing species (like M. tuberculosis, M. 
bovis BCG) while species which take less than seven days are known as rapid growers (like 
M. smegmatis, M. fortuitous) (211). 
 The generation time of M. tuberculosis is ~24 hours. Low concentrations of bacteria 
and long generation periods and long incubation times lead to diagnostic delays. Also, its 
state of dormancy and its ability to remain in the infected tissue inactive further aggravate 
the situation. Failure to detect the disease in time leads to secondary drug resistance, 
continued transmission and ultimately to death (212). Mycobacterial cell structures are 
very different from other bacterial cells that further complicate matters.  
5.2 Transmission 
 M. tuberculosis is unable to replicate in inanimate environments, and it spreads 
from one human to another through the air. When an infected person coughs, sneezes or 
talks, the aerosolized sputum containing the bacilli is generated. Droplet nuclei containing 
organisms may also be produced during sputum processing. When these droplet nuclei 
containing organisms are inhaled by another person, and they reach the alveoli within the 
lungs, they can replicate (213). For healthy humans, the host immune systems kick in and 
prevent such replication. However, if the bacilli remain viable but dormant, they result in 
latent TB. For immunocompromised humans, the mycobacteria can replicate in the lungs 
and result in the spread of TB. After inhalation of the organisms, viable bacteria can 
multiply within the alveolar macrophage every 25 to 32 hours (213). As it reaches a 
concentration of 103 to 104 in number in about 2 to 12 weeks, it elicits host immune 
response (213). The transmission of TB is determined by the following factor – (a) duration 
of for which a person is exposed to the infecting bacilli, (b) the immune system of the 
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exposed person, and (c) the number and concentration of the causative organism in the air.  
5.3 Staining  
Both gram-positive and gram-negative bacteria contain peptidoglycan which is 
composed of repeating N-acetyl-β-D-glucosaminyl-(1-> 4)-N-acyl-muramic acid units 
cross-linked by short peptide chains (209). Gram-positive bacteria have thick 
peptidoglycan layer in the cell walls while gram-negative bacteria contain an outer 
membrane outside the thin peptidoglycan layer (209). As a result, when gram-staining is 
done, gram-positive bacteria retain the color of crystal violet and appear purple in color 
when looked under a microscope. However, when gram staining (using alcohol), gram-
negative bacteria do not retain the color of crystal violet during the decolorization step. The 
outer membrane of a gram-negative cell degrades, the cell wall becomes porous, and the 
counterstain can penetrate the cell wall. As a result, gram-negative bacteria appear red 
when observed under a microscope. However, mycobacterial species differ from other 
bacteria cells; gram staining cannot be done for them. Unlike other bacteria, the 
mycobacteria cell wall is much thicker and waxy, and rich in mycolic acid. They contain 
several fatty acids like waxes, phospholipids, mycoserosic and phthienoic acids. The 
presence of mycolic acid (having carbon atoms ranging from 70-90) and other free lipids 
provide hydrophobicity to the cells (209). They have a unique IV cell wall structure which 
consists of a hydrophobic mycolic acid and peptidoglycan layer held together by 
arabinogalactan (209). The mycobacterial organisms do not stain by gram staining and 
appear as ‘ghosts.'  To visualize mycobacteria under a microscope, they need to be acid-
fast stained. Carbol fuchsin forms stable complexes with mycobacterial cell walls and can 
retain the stain as seen in figure 5-1(a) and (c). When decolorization is done using acid-
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alcohol solution, the cell walls retain the stain. As these organisms can resist decolorization 
even with acids, they are known as acid-fast bacteria. Further, when counter stains like 
methylene blue are used, they make the visualization, of the acid-fast organism under the 
microscope, much easier. Techniques like Ziehl-Neelson, Kinyoun staining, are used. 
Upon staining the mycobacteria appear as pink or bright red and have long, rod-shaped 
structure (211). 
Figure 5-1 (a) Kinyoun acid fast staining of M. bovis BCG (b) SEM image 
of M. bovis BCG, (c) Kinyoun acid fast staining of M. smegmatis (b) SEM 
image of M. smegmatis. 
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5.4 Structure 
 Mycobacteria are long, rod-shaped organisms (1-10µm long X 0.2-0.6 µm wide) 
(26, 211). They may be slightly curved or straight as seen the SEM images of M. bovis 
BCG and M. smegmatis in figure 5-1 (b) and (d) respectively. The colony morphology 
varies with the species. The colonies range from being smooth to rough. M. tuberculosis 
(on Middlebrook 7H10 agar) have dry, rough-edged colonies with a wrinkled surface. 
Mycobacteria tend to clump to one another producing strand-like structures as shown in 
figure 5-1(b). 
5.5 Digestion and Decontamination 
 Clinical samples obtained from patients are rarely pure samples (that is, they 
usually have a mixture of two or more microorganisms). For example, a clinical sputum 
sample from a patient suffering from TB will have, in addition, to M. tuberculosis has S. 
aureus, P. aeruginosa, S. epidermidis etc (214, 215).  As the mycobacteria have long 
generation periods, other bacterial species tend to overgrow in the samples. Hence, for 
proper identification and detection of mycobacteria, the clinical samples need to be 
pretreated (digested and decontaminated) to kill all non-mycobacterial species before being 
subjected to any form of processing/ detection technique. The process of digestion and 
decontamination enable us to eliminate the contaminants (all bacteria other than 
mycobacteria) and isolate mycobacteria from the samples.   
 There are several methods proposed for decontamination. Sodium hydroxide 
(NaOH), is commonly used for decontamination. However, it has been found that strong 
alkali tends to affect the mycobacteria as well during decontamination. Hence, one should 
target to achieve milder decontamination technique with effective control over the 
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contaminating bacteria. A combination of N-Acetyl-L-cysteine (NALC) and NaOH is 
preferred by several researchers as an effective decontaminant and is considered as a gold 
standard (215, 216). NALC also serves as an effective mucolytic agent and help in reducing 
the viscosity of the sputum samples. Liquefying the sputum ensures that the chemicals can 
reach all the contaminants and eliminate them. The use of NaOH-NALC solution for 15 
mins followed by addition of phosphate buffer solution (PBS) dilutes the harsh effect of 
NaOH. Following this steps, the sample is centrifuged to ensure homogenization. The 
supernatant is discarded, and the pellet is resuspended in appropriate culture medium for 
the mycobacteria to grow.  
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CHAPTER 6 
6 RAPID CULTURE-BASED DETECTION OF LIVING MYCOBACTERIA USING 
MICROCHANNEL ELECTRICAL IMPEDANCE SPECTROSCOPY (M-EIS) 
The material presented in this chapter is under review as “Rapid culture-based detection 
of living Mycobacteria using microchannel Electrical Impedance Spectroscopy (m-
EIS)” 
Roli Kargupta, Sachidevi Puttaswamy, Aiden J. Lee, Timothy E. Butler, Zhongyu Li, 
Sounak Chakroborty and Shramik Sengupta 
in Biological Research. 
 
Multiple techniques exist for detecting mycobacteria, each having its advantages 
and drawbacks. Among them, automated culture-based systems like the BACTEC-
MGITTM are popular because they are inexpensive, reliable and highly accurate. However, 
they have relatively long “time-to-detection” (TTD). Hence, a method that retains the 
reliability and low-cost of the MGIT system, while reducing TTD would be highly 
desirable. Living bacterial cells possess a membrane potential, on account of which they 
store charge when subjected to an AC-field. This charge storage (bulk capacitance) can be 
estimated using impedance measurements at multiple frequencies. An increase in the 
number of living cells during culture is reflected in an increase in bulk capacitance, and 
this forms the basis of our detection.   
M. bovis BCG and M. smegmatis suspensions with differing initial loads are 
cultured in MGIT media supplemented with OADC and Middlebrook 7H9 media 
respectively, electrical “scans” taken at regular intervals and the bulk capacitance estimated 
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from the scans. Bulk capacitance estimates at later time-points are statistically compared 
to the suspension’s baseline value. A statistically significant increase is assumed to indicate 
the presence of proliferating mycobacteria.  Our TTDs were 60 and 36 hours for M. bovis 
BCG and 20 and 9 hours for M. smegmatis with initial loads of 1000 CFU/ ml and 100,000 
CFU/ml respectively. The corresponding TTDs for the commercial BACTEC MGIT 960 
system were 131 and 84.6 hours for M. bovis BCG and 41.7 and 12 hours for M smegmatis, 
respectively. This proves that our culture-based detection method using multi-frequency 
impedance measurements is capable of detecting mycobacteria faster than current 
commercial systems.  
6.1 Introduction 
Tuberculosis (TB) is a chronic disease with a high mortality rate. According to a 
recent WHO report, it is estimated that about 1.5 million people died from TB in 2013 
(217). However, proper and timely diagnosis and treatment can reduce the mortality rate 
and the economic burden associated with TB (217, 218). An early diagnosis of TB would 
yield two benefits. Firstly, clinical intervention (treatment with first-line antibiotics) is 
initiated sooner and secondly, drug susceptibility testing (DST) can be completed earlier, 
leading to tailored treatment of patients according to the DST results (219) and prevent the 
widespread transmission of drug resistant strains.  
 Various diagnostic techniques are available to clinicians to identify patients with 
TB and/or detect mycobacteria in patient samples. Common diagnostic techniques include 
serial sputum smear microscopy and chest X-ray. However, these techniques suffer from 
poor specificity and/or sensitivity (have high rates of false negatives) and information on 
drug susceptibility is lacking (217, 219-221). An alternative testing method is the Mantoux 
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tuberculin skin test (TST). In Mantoux TST, the response to the injection of a small dose 
containing M. tuberculosis derivatives is observed at different time intervals. However, 
this test suffers from low specificity and the interpretation of the obtained test results is 
subjective (218). Other techniques include polymerase chain reaction (PCR) based rapid 
diagnostic tests (222-224). The Xpert MTB/RIF is a nucleic acid amplification technique 
that can detect the presence of mycobacteria in less than 2 hours, and has a limit of detection 
of 131 CFU/ml in sputum (225). However, it suffers from a couple of limitations when 
compared to automated culture based systems. Firstly, the limit of detection of culture-
based systems is 1 CFU in the sample (226, 227). Second, the reagents/chemicals used are 
sometimes unstable in “real-world” situations (220), which is not the case for disposables 
of the culture-based systems (growth media). Finally, whereas a hardware unit for culture-
based system (BD Bactec 9120 that handles 120 Myco/F-lytic bottles simultaneously) costs 
~$20,000 and disposables cost < $10 per test, the costs are significantly higher for the Xpert 
(228). The XpertMTB/RIF instrument (with 4 modules that can run 16-20 tests per 8 hr 
shift) has an unsubsidized cost of ~$34,000 and each single use cartridge has a cost of ~$40 
(229). The high cost is especially daunting to end-users (hospitals) in low to mid-resource 
environments, where the great majority of TB cases occur. While, a consortium of 
charitable organizations that include the Foundation for Innovative New Diagnostics 
(FIND), the Gates Foundation, USAID and UN agencies, provide a 50% subsidy on the 
instrument and a 75% subsidy on the disposables, making the XpertTM instrument available 
for  $17,000 and disposables available for ~$10 a test, such funding is limited and available 
to only a few select “approved” users. Hence, culture based testing is still considered the 
gold standard (217) because of its limit of detection of 1 CFU and still widely used (230) 
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due to their relatively low cost. 
Culture based detection is cheap, reliable, highly accurate and can be used for DST 
against multiple drugs and drug combinations (217). It has been found that in comparison 
to solid media, mycobacteria grow much faster in liquid media (231). Currently a number 
of culture-based methods for detection of TB is available such as broth micro-titer based 
microscopic observation drug susceptibility (MODS) assay and automated liquid culture 
based diagnostic systems such as the BD BACTEC 960 MGIT fluorometric system, 
BACTEC 460 TB System and Biomerieux’s BacT/ALERT 3D system for detecting 
mycobacteria in samples. MODS assay, though inexpensive and has an average time-to-
detection (TTD) of ~8 days (232), requires training and technical expertise of the personnel 
(231). On the other hand, automated liquid culture-based systems only need sample to be 
prepared and loaded into the instrument. A major drawback of these broth based culture 
systems (automated, or otherwise) is that they are time consuming, with most positive 
clinical samples having TTDs of ~ 14 days (for MGIT system) (233). Also samples are 
typically incubated for at least 6 weeks before being deemed negative (234, 235). Hence, 
a system for detecting mycobacteria that retains all the advantages of current automated 
culture-based systems like the MGIT system while requiring less time for results, is likely 
to be welcomed by users. 
In 2010, Association of Public Health Laboratories (APHL) and the US Centers for 
Disease Control and Prevention (CDC) launched a 118- questions survey to assess the 
capabilities and capacities of TB testing facilities in United States (230). Of the 656 
respondents, 580 (~88%) of them had know-how for implementing TB testing. Out of 
them, 466 facilities used primary broth based culture and 356 (~76%) of them used 
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semi/fully automated culture base systems. (The University of Missouri Hospital also uses 
a fully automated culture system viz. the BACTECTM MGIT TM 960 System from BD).  
TB detection in bacterial suspensions by automated broth-based culture system 
takes a long time, chiefly because of the mechanism by which these systems operate. The 
semi-automated BACTEC 460 TB system uses Middlebrook 7H12 broth medium 
containing radioactive 14C radioisotopes, and uses radiometric detection of 14CO2 released 
to detect the presence of active microorganisms (mycobacteria) (236, 237). MGIT 960 
systems, on the other hand, contain an oxygen-quenched fluorochrome that changes color 
as oxygen levels in the media change. MGIT 960 systems, hence, detect the depletion of 
oxygen inside the tubes as living mycobacteria consume oxygen (238). Similarly, systems 
like Versa TREK and MB/BacT-Alert are based on monitoring headspace pressure changes 
of sealed bottles/tubes (237) and monitoring the pH change of the media, respectively 
(239). Thus, all these automated culture-based systems share a basic operating principle 
viz. they sense changes in medium properties (O2/CO2 levels, pH etc.) brought about by 
mycobacterial metabolism as a marker for actively respiring/proliferating microorganisms. 
In this respect, they are similar to automated systems used for other applications such as 
blood culture (BACTECTM and BacT/AlertTM) or food quality testing (RABIT, Malthus 
2000 etc.) (205).   
The term “Impedance Microbiology” is often used to describe techniques that are 
based on the ability of microorganisms to alter the electrical properties of their growth 
media. The fact that microbial metabolism causes an increase the conductivity of the 
medium by breaking down less conductive species like sugars and proteins into more 
conductive ones such as lactic/pyruvic/carbonic acids and urea/ammonia was first reported 
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by Stewart in 1899 (240),  and was studied in a quantitative manner by Cole (241).  
After the development of more accurate and robust instruments to measure and 
monitor impedance, this approach became more feasible to implement in a lab setting. A 
number of researchers began investigating this method more rigorously and started to 
explore the use of this technique as a means to detect the presence of bacteria in various 
settings. In particular, it was discovered (242) that two distinct sources contribute to any 
measured electrical signal (impedance): the bulk solution and the electrochemical interface 
of the solution and the electrodes in direct contact with it. The bulk solution typically 
contains two types of species: (a) relatively mobile  ions (such as Na+, K+, Cl-, PO4
3- etc.) 
that move through the solution overcoming drag by the solvent molecules on the 
application of an electric field,  and (b)  larger, relatively immobile species such as proteins 
and cells that either carry native charge or on which charges could be induced on applying 
an electric field. Thus, as shown in Figure 6-1(a), the bulk could be represented by a resistor 
and capacitor in parallel, and the electrochemical interface of the electrode and solution, 
which consists largely of ions in chemical equilibrium with the bulk, could be represented 
by a capacitor in series with the resistance of the electrode itself (205, 242). By increasing 
the number of ionic species present, bacterial metabolism is found to affect not only the 
bulk resistance (243), but also the surface capacitance (244, 245) since the latter arises from 
ions in chemical equilibrium with those present in the bulk . A more rigorous analysis of 
the relative quantitative contributions of the bulk and the interface to the 
overall  capacitance (246) found that at operating frequencies of 1 MHz and lower, the 
contributions from the bulk capacitance (a.k.a. the geometric capacitance) and the 
interfacial capacitance were of the order of picofarads (10-12 F) and micro to nano farads 
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(10-6 to 10-9 F), respectively. Thus, while it is known that exposure to an AC field causes 
charge accumulation at the membrane of cells with non-zero membrane potential (living 
cells) (206), it logically follows that an increase in the number of cells in suspension would 
result in increased charge storage (bulk capacitance). Measuring changes in bulk 
capacitance brought about by an increase in the number of suspended cells, however, was 
not considered feasible. The consensus was explicitly stated in a review article by Munoz-
Berbel et al.(247), who wrote that 
“Geometric capacitance… due to the solution between the electrodes …. Because of its 
small value, in the picofarad range, it can usually be neglected in the measurement 
frequencies used in biosensor applications”    
Our early work (205) at attempting to measure changes in bulk capacitance (Cb) 
relied on using geometric effects to enhance the effect of changes in Cb to the measured 
reactance (X) (the “imaginary” or “out-of-phase” component of the impedance). As shown 
in Figure 6-1(b), the use of long narrow microfluidic channel causes a larger fraction of the 
electrical flux lines to interact with the (few) microorganisms present. Another way to look 
at the effect is to study the equation embedded in Figure 6-1(a). Since for any given 
material, the resistance is inversely proportional to cross-sectional area and directly 
proportional to length, the long narrow geometry results in an increase in bulk resistance 
(Rb). It can be seen that for the reactance (X), the Cb is always multiplied by Rb. Thus, any 
changes to the value of X due to a change in Cb will be “magnified” by the higher Rb. Since 
the RbCb is also multiplied by the frequency (ω), this effect is further enhanced at high 
frequencies. The geometric effect alone allowed us to detect changes in Cb that was 
previously considered too small to measure.    
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We further enhanced the sensitivity of our measurement technique by using AC 
signal with higher frequencies (ω) as high as 100MHz. At these frequencies, the charge on 
the electrode reverses every ~10nsec (as opposed to 1 µsec or longer for signals of 
frequency 1 MHz or lower). A consequence of this is that, certain assumptions that we had 
previously made regarding the electrical behavior of the solution, no longer hold. For 
instance, the model shown in Figure 6-1(a) assumes that the capacitances (bulk and 
interfacial) were ideal. In an ideal capacitor, charges accumulate instantaneously. 
However, in cases like ours charge carriers are ions that are slow and bulky compared to 
electrons, and may take as long as  hundreds of nanoseconds to complete the process of 
accumulation at the electrode (248). Hence, when fitting data, we replace the ideal 
capacitors in equation in Figure 6-1a with Constant Phase Elements (CPEs)(as shown in 
figure 6-1c).The impedance of a CPE is mathematically given (204) by 
𝑍𝐶𝑃𝐸  =  0 + 1/(𝑗𝜔)
𝛼𝑄 
……………………………………………………………..….(1) 
as opposed to an ideal capacitor, whose impedance is given by   
𝑍𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑜𝑟 =  0 +   1/𝑗𝜔𝐶 ………………………………………………………….…..(2) 
Q is the magnitude of the CPE and α is its phase. It can be seen that when α equals 1, the 
two equations are identical.  In addition, at the high frequencies we deal with (up to 
100MHz), the inductance of the wires connecting to the test circuit (the electrodes in 
contact with the aqueous suspension) can no longer be neglected. It is given by 
𝑍 =  0 +  𝑗𝜔𝐿,   ………………………………………………………………………...(3) 
where, L is the inductance and ω is the angular frequency of the applied voltage. While this 
results in a more complicated circuit model with 7 parameters (the resistances of the 
90 
 
electrode and solution, the magnitudes and phases of the CPEs at the electrode and in the 
bulk, and the connection inductance), we use a large number of data points (Z at 200 
different frequencies) and commercially available software for electrochemical analysis 
(Z-view ™) to obtain the values of our parameters.  
By being able to detect small changes in Cb, our measurement method can tell us 
when the bacterial numbers in suspension are increasing, even when their values are 
Figure 6-1 Electrical model and cassettes used for impedance measurement. (a) 
Electrical model representing two electrodes submerged in a microorganism 
suspension enclosed in a thin capillary channel (b) 3D printed long and narrow 
microfluidic channels with two gold electrode inserted for impedance measurement 
(inset) and schematic showing electrical lines of forces between two electrodes in the 
channel [205] (c) Modified electrical model which uses CPE instead of ideal capacitors 
to detect the presence of microorganisms in a suspension. 
91 
 
extremely low (~1000 CFU/ml). It can hence serve as a faster alternative to traditional 
automated culture-based detection methods like those discussed earlier. We have earlier 
demonstrated that our method is able to achieve faster times-to-detection (TTDs) in 
suspension with low initial loads (< 100 CFU/ml) for applications such as food quality 
testing (3) and blood culture(249). In both cases, we obtained 4-10 fold reductions in TTD, 
when compared to commercially available culture based systems like BACTEC etc. (249). 
In this work, we seek to demonstrate (a) a similar approach can also be used to detect/ rule 
out the presence of mycobacteria in broth based culture systems, and (b) that systems using 
our approach would have a lower TTD than state of the art culture-based detection systems 
like MGIT 960 system, Versa TREK and MB/BacT-Alert. We believe that shorter TTDs 
may turn out to have clinical relevance in the early diagnosis (and hence treatment) of 
persons with TB. 
6.2 Method 
6.2.1 Background and Overview 
Mycobacterium bovis BCG and Mycobacterium smegmatis is used instead of 
Mycobacterium tuberculosis (Mtb) to demonstrate the applicability of our method in-vitro 
since they are easier and safer to handle under BSL-2 laboratory condition (250, 251). M. 
bovis BCG, like Mtb, is a slow growing mycobacterium with a doubling time of ~20 hours 
(252). M. smegmatis, on the other hand, is a rapidly growing mycobacterial species having 
a doubling time of ~3 hours, but has membrane properties similar to Mtb (253, 254). 
To ensure absence of other bacterial contaminants all suspensions are frequently 
stained by Kinyoun staining. To visualize mycobacteria, acid-fast staining is used as the 
presence of mycolic acid in the cell walls prevent other staining protocols from working 
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(26, 255).  
Figure 6-2 shows the broad outline of the experimental protocol. Individual 
Figure 6-2 Experimental set-up for determining TTD of mycobacteria. 2 sets of 
similar samples are prepared by inoculating with mycobacteria and incubated at 37C. 
One set is sent to the Hospital microbiology lab for detection using MGIT 960 
automated culture-based system while the other set of sample is tested using our 
technique. For our technique, at regular intervals of time, small aliquots of sample 
are drawn and its impedance is tested using impedance analyzer. The data is fitted to 
an equivalent circuit to generate a Nyquist plot [259] and thereby estimates the 
values of the desired circuit parameters. We show on the graph three sets of data: 
those obtained at 2 hr, 8hr, and 12hrs for a culture of M. smegmatis (large, medium, 
and small semi-circles). The inset shows the software output for circuit parameters 
obtained by fitting the data at 12 hrs to the circuit.    
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steps/procedures are described in detail later. Briefly, active cultures of M. bovis BCG and 
M. smegmatis are created in BD MGIT media and Middlebrook 7H9 media respectively 
with initial loads of 1X103 and 1X105CFU/ml. One set of cultures is sent to an external lab 
for analysis using an automated system (BD BACTEC MGIT 960). The automated system 
records when individual culture-tubes are placed into it, and when growing mycobacteria 
are detected by it for each individual tube, thus allowing us to easily obtain the time-to-
detection (TTD). The other set is analyzed in our lab using our method.  
In our method, tubes containing the cultures are incubated at 37oC. Periodically, 
aliquots from these growing cultures are withdrawn and placed within a 3D printed 
microfluidic cassette with 1 mm diameter micro-channels (Figure 6-1b). Microchannel 
Electrical Impedance Spectroscopy (m-EIS) data is obtained from the cassette and analyzed 
to obtain the bulk capacitance (Cb). Multiple sampling is done to ensure repeatability. Cb 
values are compared with the baseline (initial) values, and the time taken for the measured 
values to become larger than the baseline (with statistical significance) is our TTD.   
Control samples containing growth media but no microorganisms are also analyzed 
similarly. TTDs of similarly prepared samples (containing approximately the same initial 
load of microorganisms) for the two methods (ours and that of the MGIT system) are 
compared. 
6.2.2 Mycobacterial cell culture 
Slow growing acid-fast organism M. bovis BCG (ATCC® 35734™) and rapid 
growing mycobacteria M. smegmatis (ATCC 700084) are used. Colonies of these 
mycobacteria are obtained by plating on egg based Löwenstein-Jensen plates for M. bovis 
BCG and 7H10 agar plates for M. smegmatis. Suspension cultures of the same are obtained 
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by inoculating BD MGIT media supplemented with mycobacteria growth supplements in 
the case of M. bovis BCG, and Middlebrook 7H9 broth supplemented with 0.05% Tween 
80 and Middlebrook Albumin Dextrose Catalase supplements (ADC) in the case of M. 
smegmatis. During sub-culturing, the bacterial suspension is incubated at 37⁰C with 
continuous agitation. The optical density (OD) mid-log cultures of the microorganisms are 
then adjusted to OD600 = 0.05 for M.bovis BCG and OD600 = 0.1 for M. smegmatis using a 
spectrophotometer which corresponds to a value of 5*106 CFU/ml and 1-5*107 CFU/ml 
respectively for use in the study (256-258). 
6.2.3 microchannel Electrical Impedance Spectroscopy (m-EIS) 
The basic principles governing the use of m-EIS to detect microorganisms have 
been described in our prior work (3, 249, 259). Briefly, the protocol requires us to 
periodically (every 12-24 hours for M. bovis BCG, and 2-4 hours for M. smegmatis) 
perform an electrical “scan” of sample aliquots in a microfluidic cassette, wherein we 
measure electrical impedance at multiple (200) frequencies ranging from 1 kHz to 100 
MHz. The cassette contains a 1mm diameter microchannel with two gold electrodes, 1 cm 
apart in the channel. An AC voltage of 500 mV is applied across the two gold electrodes, 
using an Agilent 4294A Impedance Analyzer. At each frequency (ω), both the in-phase 
and out-of-phase components of the electrical impedance, Z, (resistance (R) and reactance 
(X)) are measured. In order to take the EIS measurements (scans), all aliquots from a given 
culture (across the different points in time) are introduced into the same individual 
cassette.  As the cassettes used are handmade their readings vary from each other slightly 
and hence the data (values of bulk capacitance obtained) is scaled with respect to the value 
at the initial point in time (on the same cassette) to account for the cassette to cassette 
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variation. 
The Z vs. ω data is fitted to an equivalent electrical circuit shown in Figure 6-2 
using a commercially available software package (Z-viewTM). The software provides an 
estimate for the various circuit parameters, including the “bulk capacitance”, which 
happens to be our parameter of interest – that provides a measure of charges stored in the 
interior of the suspension (away from the electrodes). It may be noted that the bulk 
capacitance is represented as a constant-phase element (CPE) to account for the non-ideal 
nature of the capacitance at cell membranes. The magnitude of the CPE, thus, reflects the 
amount of charge stored at the membranes of living microorganisms in suspension. Any 
increase in the number of microorganisms in suspension should hence, in theory, lead to 
larger amounts of charged stored in the interior of suspensions, and hence lead to a higher 
bulk capacitance (CPEb-T) over time.  
When observing a given suspension suspected of harboring proliferating 
microorganism, our problem reduces to asking the question of “Is the current value of the 
bulk capacitance significantly greater than its value at the initial point in time?” To enable 
us to answer this question with a greater degree of confidence, for each sample, capacitance 
of 4-5 replicates are measured at specified time interval and statistically compared to 
baseline using Mann-Whitney U test. The earliest time point at which a significant 
difference is found, is defined as the TTD by m-EIS. Details of the statistical method are 
provided below. 
6.2.4 Statistical analysis 
Statistical analysis is performed in Microsoft Excel using Mann Whitney U-test. 
This non-parametric test compares if the population average between two groups is 
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significantly different or not (260). We chose to adopt the Mann-Whitney U-test over the 
more popular tools like t-test since we have only a few data points (bulk capacitance 
readings) per time point (5 for M. bovis BCG cultures, 4 for M. smegmatis cultures). More 
importantly, the normality assumption of the reading which is required for a t-test is not 
appropriate for our data. To check if the average of the bulk capacitance obtained at a time 
interval is significantly different from the bulk capacitance reading obtained in the first 
reading, the mean of the readings taken at the latter point in time is compared with the 
mean of the readings at the beginning of the culture (baseline values) and the U values 
corresponding to a p -value of 0.05 (level of significance of 5%; two tailed test) are 
calculated. Our null hypothesis is that the two bulk capacitance values are equal and the 
alternate hypothesis is that there is a significant difference between the bulk capacitance 
values. The Mann-Whitney U value obtained for our readings is compared to the critical U 
value (2 in the case of M. bovis BCG cultures where we had 5 readings at each time point 
and 0 in the case of M. smegmatis cultures where we had 4 readings at each time point) 
(260). If the Mann-Whitney U value obtained is equal to or less than the critical value, the 
null hypothesis is rejected, which means that there is a significant difference between the 
bulk capacitance values at the two time points. The earliest point in time where the U values 
obtained are equal to, or lower than, the critical U value is our time-to-detection (TTD) for 
a given sample. 
6.3 Results 
Six different kinds of suspensions are studied: Two of them contained M. bovis 
BCG in MGIT media with initial loads of ~103 CFU/ml and ~105 CFU/ml, respectively. 
Two other suspensions contained M. smegmatis in 7H9 media, again with initial loads of 
97 
 
~ 103 CFU/ml and ~105 CFU/ml. The other solutions are controls, consisting of sterile 
MGIT and 7H9 media. One sample each of the controls, three samples each of the 
suspensions with M. bovis BCG, and two samples each of the suspensions with M. 
smegmatis are analyzed using our m-EIS method. In parallel, one sample of each of the 
suspensions is sent to the University of Missouri Hospital Microbiology lab for analysis 
using the BD BACTEC MGITTM system. Times-to-detection (TTDs) for our method are 
compared to those of the MGIT system.  
Table 6.1: Comparison of TTD values obtained by our technique to BD BACTEC MGIT 
960 system. Compares the TTD values obtained for the various concentrations of M. bovis 
BCG and M. smegmatis by our technique and that obtained by the commercially available 
automated system BD BACTEC MGIT 960. 
M. bovis BCG 
 
M. smegmatis 
Bacterial 
concentratio
n used 
(in CFU/ml) 
Our 
technique 
TTD  
(in hours) 
(n=3) 
Hospital 
TTD 
( in hours) 
(n=3) 
 
Bacterial 
concentratio
n used 
(in CFU/ml) 
Our 
technique 
TTD  
(in hours) 
(n=2) 
Hospital 
TTD 
( in hours) 
(n=2) 
Control - no 
bacteria 
added 
No 
growth No growth 
 
Control - no 
bacteria 
added No growth No growth 
100,000 36 ± 0 84.6 ± 0.58 
 
100,000 9 ± 1.41  12 ± 0.71 
1,000 60 ± 0 131 ± 11.79 
 
1,000 20 ± 0 41.7 ± 0.35 
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Bulk capacitance values obtained on studying cultures initially containing ~103 
CFU/ml and 105 CFU/ml of M. bovis BCG are shown in figure 6-3 (a) and (b) (along with 
the corresponding control). As shown in the table included as part of the figure, a 
statistically significant increase in the value of the bulk capacitance is seen at 60 hours for 
103 CFU/ml and 36 hours for 105 CFU/ml in all three cases. Similar plots are shown for 
the suspensions with initial loads of ~103 CFU/ml of M. smegmatis and ~105 CFU/ml of 
M. smegmatis are shown in figures 6-4 (a) and (b) respectively. The TTDs obtained for 
each type of suspension using our method, and the TTD for similar solutions using the 
commercially available system (MGIT) is shown in Table 6.1.   
6.4 Discussion 
For both mycobacterial species, and for both initial loads in each, our times-to-
Detection (TTDs) are lesser than the corresponding TTDs obtained by the hospital using a 
Bactec MGIT 960 system. Also, the lower the initial load, and the longer the organism’s 
doubling time, more is the time saved. It is thus anticipated that the difference in TTDs 
with our method and the commercially available culture based methods similar to those 
employed by the MGIT system, will be even greater for clinical samples containing M. 
tuberculosis (Mtb), since the doubling time of Mtb is even greater than that of M. bovis 
BCG, and the initial loads can be an order of magnitude lower than what we tested (~1000 
CFU/ml).  There are non-culture based systems like Xpert MTB/RIF which have a low 
limits of detection and can do rapid detection of mycobacteria (~2hrs), these devices and 
reagents used are expensive. However, our technique, based on using the same reagents as 
that of the BACTEC MGIT 960 (and compatible with other reagents used for growing 
mycobacteria) will be cost-effective and will cut down the TTD considerably when 
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compared to automated culture-based system. 
We believe that our technique of detection, though faster, will have similar 
sensitivity and specificity as the existing culture based automated system. Human sputum 
from patients with TB contain not only mycobacteria, but also a large number of other 
gram-positive and gram-negative bacteria (214). The current protocol for detecting 
mycobacteria using MGIT and similar automated culture based systems requires the user 
to first carry out a “decontamination” step that eliminates all the non-mycobacterial 
pathogens while preserving M. tuberculosis. Standard decontamination protocols exist, 
whose efficacy at killing non-mycobacterial pathogens while keeping M. tuberculosis cells 
viable and culturable has been extensively documented (211, 216, 261, 262). Nevertheless, 
it is not unheard of for non-mycobacterial species to survive decontamination, or for the 
process to kill or render unculturable some or all of the mycobacteria present (215, 263). 
The former case leads to false positives, and the latter to false negatives in currently used 
automated culture-based systems like the MGIT.  Another source of false positives is 
contamination during handling and processing, either with mycobacteria or with non-
mycobacterial species (264). On the other hand, false negatives can also arise due to 
inefficient sampling, wherein the sample of sputum used does not contain any M. 
tuberculosis cells (although the patient does have TB). This is more likely for patients with 
low mycobacterial loads (264).  When deployed for handling clinical samples, our system 
will also require the user to perform the same decontamination process that is used before 
placing the sample in other culture-based systems, and hence we will face the same 
potential pitfalls (mentioned above) that other systems face. Hence, we expect our 
diagnostic sensitivity and specificity to be similar to that of current systems like the MGIT 
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system. Also, our limit of detection should remain 1 CFU, as with other culture-based 
systems.   
For use in our system, we would require sample pre-treatment (decontamination) 
to be done using the same protocols that are currently used before samples are loaded into 
automated systems like MGIT. The sputum obtained from different people will be different 
and hence the initial Cb value will be different and will vary from person to person. 
However, in all cases, we will be looking for significant increases from the baseline value 
(whatever that value may be).  A similar approach (looking for changes from the baseline-
value) has been used successfully used to detect the presence of living bacteria in blood 
Figure 6-3 TTD of M. bovis BCG samples. The plot of bulk capacitance obtained over 
time for samples with (a) low initial loads (~1x103 CFU/ml) and (b) high initial loads 
(~1x105 CFU/ml) for M. bovis BCG. The error bars indicate the standard deviation of the 
readings (n=5) taken at each time interval. Statistical analysis is used to compare the 
baseline reading with the various time interval readings (Ucritical=2). [Note: NSH = Not 
significantly higher, SH = Significantly higher] 
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Figure 6-4 TTD of M. smegmatis samples. The plot of bulk capacitance obtained 
over time for samples with (a) low initial loads (~1x103 CFU/ml) and (b) high initial 
loads (~1x105 CFU/ml) for M. smegmatis. The error bars indicate the standard 
deviation of the readings (n=4) taken at each time interval. Statistical analysis is 
used to compare the baseline reading with the various time interval readings 
(Ucritical=0). [Note: NSH = Not significantly higher, SH = Significantly higher] 
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culture broth (249). Like sputum, blood drawn from different people have different bulk 
capacitance values to start with.  By looking for a significant increase in the Cb value from 
their respective initial values, we are able to account for sample-to-sample variations. 
Therefore, any change in the Cb value will be due to the change in the number of 
mycobacteria present in the sample.  
An important limitation of the system as implemented in the work presented here 
is that aliquots are manually withdrawn at select points in time. With support from the NIH 
via a Phase II SBIR award (No R44-AI096572-02), our industry partners (Techshot Inc., 
and ImpeDx Diagnostics), are currently developing an automated blood culture system that 
includes an automated sampler. Such a system, which could be readily adapted for 
detecting mycobacteria in cultures as well, will be tested against standard of care 
equipment (Bactec and similar) in multiple locations. 
When trying to detect mycobacteria via culture, our times-to-detection (TTDs) are 
much lower than those obtained using currently available culture-based detection systems 
like the MGITTM by a factor of ~2. Since clinical samples take up to 4 weeks to yield a 
positive result, an automated system implementing our method (which we plan to develop 
and optimize) could potentially obtain results many days (and sometimes even 1-2 weeks) 
faster than currently available automated culture-based systems. This is likely to yield 
significant clinical benefits in terms of improved patient outcomes.   
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CHAPTER 7 
7 DETECTION BY DEATH: A RAPID WAY TO DETECT VIABLE SLOW-
GROWING MICROORGANISMS ACHIEVED USING MICROCHANNEL 
ELECTRICAL IMPEDANCE SPECTROSCOPY (M-EIS)   
The material presented in this chapter will be submitted as “Detection by Death: a rapid 
way to detect viable slow-growing microorganisms achieved using microchannel 
Electrical Impedance Spectroscopy (m-EIS)” 
Roli Kargupta, Yongqiang Yang, Sachidevi Puttaswamy, Aiden J. Lee, Nicholas A. 
Padilla, Alec P. Foutch and Shramik Sengupta 
in a peer reviewed academic journal in the area of Bioengineering. 
 
Based on the insight that only living organisms can be killed (and that killing can 
proceed much faster than cell-growth), we present an approach for the detection of viable 
microorganisms that is much faster than currently used culture-based methods. We do so 
by using microchannel Electrical Impedance Spectroscopy (m-EIS) for real-time detection 
of cell-death on exposure to a killing-agent.  
m-EIS relies on the fact that when living-cells with non-zero membrane potentials 
are exposed to high-frequency AC-field, induced-charges accumulate at the membrane-
interface. Cell-death is accompanied by a loss of membrane-potential, and hence charge-
storage (capacitance).   
A proof-of-principle for a clinical-application (detection of living mycobacteria in 
sputum) is demonstrated. Mycobacterium smegmatis (doubling-time ~3hrs) and 
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Mycobacterium bovis BCG (doubling-time ~20hrs) in artificial-sputum are both detected 
in <3hrs when exposed to amikacin. Times-to-detection (TTDs) are ~12hrs and ~84hrs 
(3½days), respectively for culture-based detection using current technologies (BD-MGIT-
960TM) for samples containing similar loads of M. smegmatis and M. bovis BCG. 
7.1 Introduction 
 In many real-world situations, one seeks to detect viable (live) microorganisms 
present. Often, it is known or expected that there will be non-viable microbial cells also 
present in the material being investigated. In many cases, it is also of utmost importance 
that this information be obtained as quickly as possible. Examples include (but are not 
limited to) (a) the need to detect the presence of viable bacteria and/or yeasts in blood for 
patients suspected of having an active bloodstream infection (septicemia), where it is 
possible that other non-viable bacteria are also present (265, 266),  (b) the need to check 
for the presence of coliforms and other bacteria in food or water samples after they have 
been subjected to procedures such as pasteurization or disinfection (267), and (c) the need 
to detect viable cells of Mycobacterium tuberculosis in the sputum of patients suspected of 
having an active infection (given that dormant M. tuberculosis cells may be present in cases 
of “latent” TB (268), or previous treatment may have left behind some dead cells of 
M.tuberculosis (262).   
In such cases, the need to prevent false positives due to the presence of dead cells 
excludes some technologies such as DNA based methods like PCR and antibody based 
approaches like ELISA as viable options (266). Given the above limitation (presence of 
dead cells) and added constraints brought about by the desire to contain costs, and make 
the detection automated and not dependent on human judgement, automated culture-based 
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systems currently serve as the work-horses of the microbiology laboratory for these types 
of applications. Some commonly encountered automated culture based detection systems 
include blood culture systems like the BACTEC ™ from Becton-Dickinson (BD), the 
BacT/Alert ™ from Biomerieux and Versa-TREK from Thermo-Scientific, specialized 
culture systems for mycobacteria like the Mycobacteria Growth Indicator Tube (MGIT) 
from BD, and Trek-ESP from Thermo-Scientific, and products like RABIT, BacTrac, 
Malthus 2000 that are used primarily for food and water testing.   
In general, the protocol followed in automated culture-based systems require the 
user to add an aliquot of the sample of interest (blood, sputum, food etc.) into a bottle 
containing nutrient broth conducive to the target microorganisms. These microorganisms, 
if present, metabolize compounds such as sugars and proteins/peptides present in the 
nutrient broth and grow in number via reproduction. As they do so, they change the 
properties of the medium such as O2/CO2 levels, pH, electrical conductivity etc. While 
the  specific membrane property that is monitored differs from instrument to instrument, 
all automated culture based systems monitor these properties continually (every few 
minutes at the longest) and generate a notification for the user when the property has 
changed significantly from the baseline (time t=0) value. Thus, they not only provide for a 
“load and forget” user experience, but also are reliable due to their rather straightforward 
detection methods and low-cost due to their not needing expensive specialized chemicals. 
The main drawback of these instruments is the long time that they need to detect the 
presence of microorganisms. The time-to-detection (TTD) can range from 1-5 days for 
blood culture (249, 269) to up to 6 weeks for tuberculosis (234). Two factors (low initial 
load and long doubling time of the microorganisms present) adversely affect TTD. 
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Typically, due to the low absolute rate of metabolism of a small bacterial cell (it is 
estimated that even a fast-growing bacteria like E. coli consumes only 2x1014 moles of 
O2/hr (205) and hence has correspondingly low rates of CO2/acid production), the bacterial 
load in the culture tubes being monitored must rise to ~108 CFU/ml in instruments like the 
BACTEC before they are detected (270).  
Other approaches have being tried to reduce the TTD in culture-based systems. 
Gomez-Sjoberg and co-workers (271) concentrated the bacteria present in relatively larger 
volumes into a small volume using dielectrophoresis (DEP), and thus raised the effective 
starting concentration of the bacteria before trying to detect changes in solution 
conductivity brought about by the bacterial metabolism. By doing so, they obtained times 
to detection (TTDs) of ~ 2hrs for suspensions of Listeria monocytogenes  with initial loads 
of  ~105 CFU/ml (concentrated using DEP to effective initial loads of ~107 CFU/ml) as 
opposed to ~ 8 hrs to detect samples with similar loads without pre-concentration. It may 
be noted that in this case, the “threshold” concentration that must be reached for the system 
to flag the sample as positive remains similar to that of the current instruments on the 
market. The 4-fold reduction in TTD is obtained due to pre-concentration alone. On the 
other hand, in our earlier work (3, 205, 249), we developed a method that we call 
microchannel Electrical Impedance Spectroscopy (m-EIS), wherein we measure a 
parameter (charge storage in the interior of a suspension due to the polarization of 
membranes of living cells, a.k.a “bulk capacitance”) that we find to be more sensitive to 
changes in bacterial load, and using which proliferating bacteria can be detected  at 
threshold concentrations ~ 103 to 104 CFU/ml (as opposed to 108 CFU/ml in other systems). 
We thus obtained TTDs of  2 hrs for E.coli with initial loads of 100 CFU/ml (without the 
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need to resort to any pre-concentration steps) (3).     
While these approaches do reduce the long times-to-detection (TTDs) associated 
with automated culture-based systems, the TTDs remain unacceptably long for organisms 
whose metabolism is slow (doubling times are long). A clinically important example of 
such an organism is Mycobacterium tuberculosis, the organism that causes tuberculosis 
(TB) and which has a doubling time of ~24 hrs (272) (compared to ~20 min for E. coli (3)). 
Using systems currently on the market (such as MGIT ™), TTDs for clinical samples 
containing ~1000 CFU/ml can range from ~200 (8.3 days) to ~800 (33.33 days) hours 
(273). Even using our m-EIS method, we obtained only a modest (approximately 2X) 
reduction in TTD for Mycobacterium bovis BCG (a closely related biosafety level II 
organism with a doubling time of ~20 hrs (274)). [Our TTD was 60 hrs (2 ½ days) for 
initial loads of ~1000 CFU/ml, as opposed to 131 hrs (~ 5 ½ days) taken by MGIT ™ for 
a similar sample]. 
Thus the bottom line is that if one tries to detect living bacteria by asking “are they 
metabolically active?” or “do they grow?” one is limited by the growth/metabolic rate of 
the organisms (which may be unacceptably slow). On the other hand, cells can be killed at 
a much faster rate than growing them, and any technique that studies cell death in real time 
will be able to determine the presence of bacteria in a system much faster. Since only living 
cells can be killed, such a system will be able to determine the presence of viable bacteria 
in the system.  
We monitor cell death in real-time using microchannel Electrical Impedance 
Spectroscopy (m-EIS), which is a novel, patented method (275) that is distinct from 
classical “impedance microbiology” approaches. The latter methods (207) detect changes 
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to the electrical properties (either solution conductivity (244) or capacitance of the 
electrode solution interface (243), or a combination of the two (246)) brought about by 
bacterial metabolism. Viable bacteria break down sugars to more conductive species such 
as lactate and carbonate. This makes the solution more conductive. Interfacial capacitance 
(Ci) is also affected since the ions in the double-layer are in electrochemical equilibrium 
with those in the bulk. It may be noted that these methods can only distinguish between 
growth and no-growth (the former being characterized by an increase in conductivity or 
interfacial capacitance) and not between no-growth and cell death (both of which result in 
there being no changes brought about to the solution properties).   
           In contrast, our method relies on the fact that in the presence of high frequency AC 
electric fields, charge accumulates at the membranes of cells across which there exist a 
potential difference (the membrane potential of living cells) (206). The charge storages 
(capacitances) at individual cells contribute to the overall “bulk capacitance” of the 
suspension (net charge stored in the interior). When the number of living cells present 
increases (due to proliferation), the bulk capacitance increases. More importantly for the 
current work, when cells die, the membrane potential falls significantly (206), and charge 
storage under an AC field no longer occurs at the membrane. This causes the bulk 
capacitance to drop. Thus, a set of measurements showing a decrease in bulk capacitance 
over time enables us to monitor cell death.     
7.2 Methods 
7.2.1 Rationale and Overview 
Our objective is to demonstrate that the “detection by death” approach (which 
involves recording a loss of signal upon the death of microorganisms of interest) can 
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indicate the presence of viable microorganisms of interest much faster than using 
traditional approaches based on detection of growth/metabolism. We also believe that the 
most dramatic differences are likely to be observed in cases where the microorganism of 
interest is slow growing. One clinically important microorganism that takes a long time to 
be detected because of its long doubling time/slow metabolism is Mycobacterium 
tuberculosis (Mtb), which takes days (and sometimes weeks) to be detected using 
automated culture-based instruments like the BACTEC MGIT 960 (Becton Dickinson), 
MB/BacT ALERT system (BioMerieux), ESP Culture System II (Difco Labboratories) and 
Versa TREK Mycobacteria detection system (Versa TREK Diagnostics) (276).   
 One limitation which exists for samples obtained from tuberculosis-afflicted 
patients is that they contain both mycobacteria as well as non-mycobacteria species like S. 
aureus, P. aeruginosa, etc. (214). Therefore, to observe the growth dynamics/ action of the 
antibiotics on mycobacteria alone, one has to first eliminate all non-mycobacterial 
microorganisms present in the sample. There exist multiple standard protocols of digestion 
and decontamination for doing the same and companies like Becton Dickinson, Hardy 
Diagnostics etc. sell reagent kits designed to do so.  
Since Mycobacterium tuberculosis is a Biosafety Level III (BSL-III) 
microorganism, we use Mycobacterium smegmatis and Mycobacterium bovis BCG as 
surrogate organisms to demonstrate proof-of-principle. M. smegmatis is a rapidly growing 
BSL-I organism with a doubling time of ~3 hours and has membrane characteristics very 
similar to M. tuberculosis (254, 277) while M. bovis BCG is a slow growing BSL-II 
organism, whose doubling time of ~20 hours (274) is comparable to that of M. tuberculosis 
~24 hours (254, 277). We would ideally like to show that not only are we able to detect the 
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presence of these organisms quickly using our approach, but that the TTDs obtained on 
Figure 7-1 Experimental set-up to demonstrate the ability of the “detection by death” 
approach to detect the presence/absence of mycobacteria in a sputum sample (a) 
Artificial sputum sample, containing both pathogen of interest (mycobacteria) and 
commensal bacteria (gram positive and gram negative), is prepared (b) Standard 
protocol (treatment with NaOH-NALC) is used to liquefy the (artificial) sputum and 
decontaminate it (kill all non-mycobacterial microorganisms). The addition of PBS 
and centrifugation to obtain cells is also part of the protocol (c) Collected cells are 
resuspended in two broths: one containing Carbenicillin in 7H9 media, and the other 
containing both Carbenicillin and Ampicillin in 7H9 media,  (d) at regular intervals 
of time (every hour), 50ul aliquots are extracted and scanned electrically. 
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using our method are independent of the doubling time of the organisms.  
Our experimental protocol is summarized in Figure 7-1. As shown in the figure 
(panel (a)), we first create a sample of artificial sputum containing not only mycobacteria, 
but gram-positive and gram-negative bacteria as well.    
Initial loads of ~ 1x105 to 5x105 CFU/ml of bacteria are used (maintaining a ratio 
of 1:1 between mycobacteria and other bacteria). A standard protocol for real-world 
samples of human sputum that involves the use of sodium hydroxide/ N-acetyl-L-cysteine 
(NaOH/NALC) (215, 216, 278) to digest and decontaminate the simulated sputum 
samples.  This treatment kills all bacteria other than mycobacteria in the sample. Post-
decontamination and centrifugation, the sample is re-suspended in fresh media and allowed 
to incubate at 37 ˚C for 2-3 hours. Antibiotic(s) are then added to the media, and thereafter, 
at regular intervals of time, small aliquots (~ 50 ul) are withdrawn, inserted into the thin 
channels of a microfluidic cassette and subjected to electric scans.  Each scan involves 
applying a small AC voltage (500mV) at multiple frequencies ranging from 1 KHz to 
100MHz across gold electrodes in contact with the suspension and recording the 
impedances at various frequencies. The data is processed to obtain an estimate of the bulk 
capacitance, a parameter that reflects the amount of charge stored by particles in the interior 
of the suspension and is thus correlated with the number of living microorganisms present. 
The manner in which the bulk capacitance changes over a few hours after the addition of 
the antibiotic(s) provides information on the presence of viable mycobacteria 
(microorganism of interest) in the original sample. Details of the individual steps (including 
data collection, analysis, and interpretation) are provided below.   
7.2.2 Bacterial cell cultures 
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For the in vitro study, we used either Mycobacterium smegmatis (ATCC® 
700084TM), or Mycobacterium bovis BCG (ATCC® 35734TM). Staphylococcus aureus 
(ATCC 29213) and Pseudomonas aeruginosa (ATCC 27853) are chosen as our model 
gram-positive and gram-negative organisms, respectively. M. smegmatis and M. bovis 
BCG are sub-cultured in Middlebrook 7H9 media supplemented with Middlebrook 
Albumin Dextrose Catalase (ADC) supplements at 37C. The optical density (OD) value 
for M. smegmatis is adjusted to OD600=0.1 and for M. bovis BCG is adjusted to OD600=0.05 
using a spectrophotometer which corresponds to ~1X107 CFU/ml and (1-5)x106 CFU/ml 
respectively. (256, 279) All the other bacteria, other than mycobacteria are sub-cultured in 
Tryptic Soy Broth (TSB) at 37C to obtain log cultures. The OD value is adjusted to 
OD570=1.5 and OD600=0.1 which corresponds to 1x10
7 CFU/ml and 1x108 CFU/ml for S. 
aureus and P. aeruginosa respectively (280, 281). 
7.2.3 Rationale for choice of antibiotics  
Figure 7-2 shows, three different cases (rows) that are each tested under two 
conditions (columns). All tests are conducted in triplicate. The first case is a control (no 
bacteria present), the second (presence of gram positive, gram negative and mycobacteria) 
replicates the sputum of a patient with TB, and the third (absence of mycobacteria, but 
presence of other bacteria) replicates the sputum of a patient without TB. The samples of 
sputum are treated and exposed to two conditions. Under condition A, the samples are 
exposed to a cocktail of two antibiotics amikacin and carbenicillin while under condition 
B, the samples are exposed to carbenicillin only. Amikacin (32µg/ml) is obtained from 
Fisher Scientific and is known to have bactericidal effects towards M. smegmatis (282), M. 
bovis BCG (283) and M. tuberculosis (284). Carbenicillin disodium salt (25 µg/ml), 
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obtained from Research Products International Corporation, and is known to be ineffective 
against mycobacteria but bactericidal against most other non-mycobacterial species (285). 
The other possible case which is only mycobacteria and no non-mycobacterial species was 
not considered as relevant, since other commensal and pathogenic bacteria are invariably 
present in the sputum (214).  
Figure 7-2 Expected plots of bulk capacitance versus time that we expect to obtain for 
the two conditions tested (with carbenicillin and amaikacin, and with carbenicillin alone) 
for the control (no-bacteria) and two possible cases likely to be encountered 
(mycobacteria present along with commensal bacteria and only commensal bacteria 
present). 
114 
 
All m-EIS readings are done post digestion and decontamination of the samples 
using NALC-NaOH (N-acetyl-L-cysteine- sodium hydroxide) technique. In the first case, 
the sample has no bacteria. Hence, no changes in charge storage (bulk capacitance) occur 
at any point in time, and we expect to see a flat line as there should be no change in the 
bulk capacitance over time. In case three, where the sample contains gram-positive and 
gram-negative bacteria, but no mycobacteria, all organisms are killed during 
decontamination (pre-treatment) itself, and the addition of the antibiotics is not expected 
to cause any changes to the measured value of bulk capacitance. However, if there are 
mycobacteria in the sample (as in case 2), they will survive the decontamination process 
and will continue to grow in the presence of Carbenicillin (case 2B). However, they will 
die in the presence of amikacin (case 2A).  This combination (dip in the presence of 
amikacin, but not in the presence of Carbenicillin alone) will indicate the presence of 
mycobacteria. It may be noted that if the decontamination is done improperly, and some 
gram-positive and gram-negative bacteria survive, they will be killed under both 
conditions, and we can expect to see a dip in the bulk capacitance vs. time curve for both 
conditions.    
7.2.4 Digestion and decontamination 
We use artificial sputum, which is prepared according to protocols available in the 
literature (286-288). Briefly, 1L of 1% (w/v) aqueous methylcellulose solution is prepared. 
After autoclaving the same, 1 emulsified egg is added. This artificial sputum is then used 
for our experiments. The sputum processing technique adopted is based on standard 
techniques that use of N-acetyl-L-cysteine (NALC) to liquify and sodium hydroxide 
(NaOH) to decontaminate the sample (211, 261, 278). Briefly, for each 100ml of the 
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solution, 50 ml of 0.5N NaOH is combined with 50 ml of 0.1M trisodium citrate solution 
and 0.5gm of powdered NALC. 10 ml of the NALC-NaOH solution is added to 10ml of 
the sputum in a 50 ml tube and vortexed to mix. The solution is then allowed to stand at 
room temperature for 10 minutes. During this time, the sputum is digested and liquefied. 
After this, 1X PBS solution is added to make up the volume of the solution to 50 ml. The 
addition of PBS and the resulting dilution stops for all practical purposes the harmful action 
of the NaOH.  Following this, the tubes are centrifuged at >3000g for 15 minutes, the 
supernatant is decanted, and the pellet is re-suspended in 20 ml of fresh media. 
7.2.5 microchannel Electrical Impedance Spectroscopy (m-EIS) 
The basic principles governing the use of m-EIS to detect microorganisms have 
been described in our prior work (205, 249). Briefly, we sense changes in bulk capacitance 
(Cb) by relying on geometric effects that enhance the effect of changes in Cb to the 
measured reactance (X) (the “imaginary” or “out-of-phase” component of the impedance). 
As shown in Figure 7-3(b), the use of long narrow microfluidic channel causes a larger 
fraction of the electrical flux lines to interact with the (few) microorganisms present. 
Another way to look at the effect is to study the equation embedded in Figure 7-3(a). Since 
for any given material, the resistance is inversely proportional to cross-sectional area and 
directly proportional to length, the long narrow geometry results in an increase in bulk 
resistance (Rb). It can be seen that for the reactance (X), the Cb is always multiplied by Rb. 
Thus, any changes to the value of X due to a change in Cb will be “magnified” by the higher 
Rb. Since the RbCb is also multiplied by the frequency (ω), this effect is further enhanced 
at high frequencies. In addition, our electrical sensitivity is further enhanced by using AC 
signal with higher frequencies (ω) as high as 100MHz. At these frequencies, the charge on 
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Figure 7-3 (a) Electrical equivalent circuit model that represents our microfluidic 
cassette which is used for measuring the impedance of the bacteria. (b) Microfluidic 
cassettes with two gold electrodes inserted at a distance of 1 cm (inset) and 
schematic of electric lines of forces present between the two electrodes when an 
AC voltage is applied to the system. [205] (c) Agilent Impedance Analyzer is used 
to do the electrical scans at multiple frequencies and commercially available Z 
view® software is used to analyze the data to obtain the values for the various 
electrical parameters, and (d) The bulk capacitance values obtained from data 
analysis is plotted against time. The decrease in the bulk capacitance values (black 
line) is due to cell death while the rise is due to bulk capacitance (red line) values 
is due to the cell growth. 
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the electrode reverses every ~10nsec. A consequence of this is that there is not enough time 
for ions of opposite charge to completely cover the electrode, and thus the electric field is 
able to penetrate into the bulk to a greater degree and cause a greater degree of charge 
accumulation at the cell membranes.  
Our experimental protocol requires us to periodically (every hour) perform an 
electrical “scan” of sample aliquots in a microfluidic cassette, wherein we measure 
electrical impedance at multiple (200) frequencies ranging from 1 kHz to 100 MHz. As 
shown in figure 7-3b, the cassette contains a 1mm diameter microchannel with two gold 
electrodes, 1 cm apart in the channel. An AC voltage of 500 mV is applied across the two 
gold electrodes, using an Agilent 4294A Impedance Analyzer. At each frequency (ω), both 
the in-phase and out-of-phase components of the electrical impedance, Z, (resistance (R) 
and reactance (X)) are measured. In order to take the EIS measurements (scans), all aliquots 
from a given culture (across the different points in time) are introduced into the same 
individual cassette.  As the cassettes used are handmade their readings vary from each other 
slightly and hence the data (values of bulk capacitance obtained) is scaled with respect to 
the value at the initial point in time (on the same cassette) to account for the cassette to 
cassette variation.  
The Z vs. ω data is fitted to an equivalent electrical circuit shown in Figure 7-3c 
using a commercially available software package (Z-viewTM). The software provides an 
estimate for the various circuit parameters, including the “bulk capacitance”, which 
happens to be our parameter of interest – that provides a measure of charges stored in the 
interior of the suspension (away from the electrodes). It may be noted that the bulk 
capacitance is represented as a constant-phase element (CPE) to account for the non-ideal 
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nature of the capacitance at cell membranes. The magnitude of the CPE, thus, reflects the 
amount of charge stored at the membranes of living microorganisms in suspension. Any 
decrease in the number of microorganisms in suspension should hence, in theory, lead to 
smaller amounts of charged stored in the interior of suspensions, and hence lead to a lower 
bulk capacitance (CPEb-T) over time as shown in figure 7-3d.  
When trying to observe cell death in a suspension suspected of harboring living 
microorganisms, our problem reduces to asking the question of “Is the current value of the 
bulk capacitance significantly lesser than its value at the initial point in time?” To enable 
us to answer this question with a greater degree of confidence, for each sample, capacitance 
of 4 replicates are measured at specified time interval and statistically compared to baseline 
using Mann-Whitney U test. The earliest time point, at which a significant decrease is 
found, is defined as the TTD for our “detection by death” method. Details of the statistical 
method is provided below.     
7.2.6 Statistical analysis 
Statistical analysis is performed in Microsoft Excel using Mann Whitney U-test. 
This non-parametric test compares if the population average between two groups is 
significantly different or not (260). We chose to adopt the Mann-Whitney U-test over the 
more popular tools like t-test since we have only a few (4) data points (bulk capacitance 
readings) per time point. More importantly, the normality assumption of the reading which 
is required for a t-test is not appropriate for our data. To check if the average of the bulk 
capacitance obtained at a time interval is significantly different from the bulk capacitance 
reading obtained in the first reading, the mean of the readings taken at the latter point in 
time is compared with the mean of the readings at the beginning of the culture (baseline 
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values) and the U values corresponding to a p -value of 0.05 (level of significance of 5%; 
two tailed test) are calculated. Our null hypothesis is that the two bulk capacitance values 
are equal and the alternate hypothesis is that there is a significant difference between the 
bulk capacitance values. The Mann-Whitney U value obtained for our readings is compared 
to the critical U value (260). If the Mann-Whitney U value obtained is equal to or less than 
the critical value (in this case, critical value =0), the null hypothesis is rejected, which 
means that there is a significant difference between the bulk capacitance values at the two 
time points. The earliest point in time where the U values obtained are equal to, or lower 
than, the critical U value is our time-to-detection (TTD) for a given sample.   
7.3 Results 
As outlined in Figure 7-2, three different cases are studied under two conditions. 
Figure 7-4 represents the results obtained when M. smegmatis is used. The initial loads of 
the bacteria used are (1 to 5) X 105 CFU/ml. In the case of controls (Case 1A and 1B), we 
observe that there is no change in the bulk capacitance values over time and we get flat 
lines parallel to the x-axis. Also, the U-values calculated show that there is no significant 
difference between the bulk capacitances obtained at various time intervals. In the case of 
3A and 3B, the process of decontamination eliminates non-mycobacterial cells in the 
suspension and hence, in the absence of M. smegmatis, there is no significant change in the 
bulk capacitance values over time. For case 2, condition A,  where a cocktail of M. 
smegmatis, P aeruginosa, and S. aureus is exposed to amikacin and carbenicillin after 
decontamination, we see that the impedance values show a decreasing trend over time, and 
the reading after 3 to 4 hours (depending on the experiment) is lower than the baseline 
value in a statistically significant manner. The decrease in the impedance values is due to 
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Figure 7-4 Average bulk capacitance versus time graph for the 6 cases using M. 
smegmatis. S = significant difference, NS= not significant difference 
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Figure 7-5 Average bulk capacitance versus time graph for the 6 cases using M. 
bovis BCG. S = significant difference, NS= not significant difference 
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the death of the remaining M. smegmatis in the presence of amikacin. Under condition B, 
a similarly decontaminated mixture of  M. smegmatis, P aeruginosa, and S. aureus is not 
found to show any decrease over time. This is because in the absence of amikacin, the 
mycobacteria present are not killed. It is possible that the mycobacteria actually grow 
during this time, but the growth rate is too slow for us to discern any increase in bulk 
capacitance 
Similar results are obtained in Figure 7-5, where the mycobacteria used is M. bovis 
BCG. Here in case 2A, decreasing bulk capacitance was observed after 1 hour itself but no 
growth was seen in in case 2B during the duration of observation (3 hours). It may be noted 
that while we expect cells to be proliferating in Case 2B, the rate of increase in bulk 
capacitance is observed to be negligible. This is not surprising since the doubling times  
of the microorganisms is long (~20 hours for M. bovis BCG and ~ 3 hours for M. 
smegmatis), and in fact underlines the advantage in speed of our method vis-a-vis growth-
based detection approaches.   
As mentioned in Section 2.3 (rationale for choice of antibiotics), improper 
(incomplete) decontamination can lead to certain non-mycobacterial species surviving the 
decontamination step. This typically leads to false positives for culture (growth) based 
detection methods [5]. However, our approach provides a means to identify these false 
positives as well. If non-mycobacterial species are present in the sample after 
decontamination, death would be observed for both conditions A and B (unlike for 
condition A alone if decontamination is done correctly).  To simulate a case of incomplete 
decontamination, samples of artificial sputum containing a cocktail of S. aureus and 
P.  aeruginosa were exposed to NaOH-NALC for  approximately 1 minute (as opposed to 
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the 10 minutes previously used to achieve complete decontamination). Also, the NaOH 
concentration used was 0.25N (as opposed to 0.5N used to achieve complete 
decontamination). The sample thus obtained was exposed to antibiotics: both carbenicillin 
alone (condition B) and carbenicillin in combination with amikacin (condition A). As 
shown in Figure 7-6, in such a situation, we observe decreases in bulk capacitance over 
time for both conditions, unlike when decontamination is complete and mycobacteria are 
the only surviving live species (case 2, condition A).    
7.4 Discussion 
In this piece of work, we have (a) introduced the idea that live organisms can be 
detected by observing them die, (b) shown our ability to observe the death of organisms 
using m-EIS, and (c) outlined and implemented a scheme involving monitoring death (or 
lack thereof) of microorganisms in a sample upon exposure to 2 sets of antibiotics using 
which one may detect the presence of live Mycobacteria in sputum samples. The times-to-
detection (TTDs) we achieved using our method were 3 to 4 hours.  
As we observed, our TTDs are not related to the doubling times / metabolic rate of 
organisms and compares extremely favorably with those of culture-based detection 
methods: both traditional ones, and other novel approaches under development. At the 
same time, our method retains the advantages of culture-based methods by being 
potentially inexpensive (not requiring expensive chemicals with strict storage 
requirements), automatable (not subject to observer judgement) and having high 
sensitivity. Moreover, it can rule out a major source of false positives seen in traditional 
culture-based methods (incomplete decontamination).    
 In terms of TTD, our method is comparable to that obtained by Xpert® 
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MTB/RIF.  The XpertMTB/RIF instrument (with 4 modules that can run 16-20 tests per 8 
hr shift) has a cost of ~$34,000 and each single use cartridge has a cost of ~$40. However, 
a consortium of charitable organizations that include the Foundation for Innovative New 
Diagnostics (FIND), the Gates Foundation, USAID and UN agencies, provide a 50% 
subsidy on the instrument and a 75% subsidy on the disposables to “approved” public 
health agencies in low-resource countries, making the XpertTM  instrument available 
for  $17,000 and disposables available for ~$10 a test (229). A fully automated version of 
our method would consist of a fixed instrument (that would house the electric circuits), and 
disposables (cassettes / tubes with growth media and antibiotics) and is likely to be much 
Figure 7-6 Partial decontamination of simulated sputum samples containing 
non-mycobacterial cultures are exposed to two conditions namely, Condition 
A : cocktail of two antibiotics, Amikacin and Carbenicillin and Condition B: 
only Carbenicillin. Average bulk capacitance estimated from the m-EIS 
scans is plotted against time. 
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less expensive. An inexpensive device that is able to rapidly detect TB in human samples 
is a pressing global-health need.  
Of course, we would have to build such an instrument, as well as demonstrate that 
our method works on M. tuberculosis present in actual human sputum (instead of M. bovis 
BCG in artificial sputum). We plan on doing both in the near future.   
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CHAPTER 8 
8 CONCLUSION AND FUTURE WORK 
Microorganisms are present everywhere. When the pathogenic microorganisms 
enter our body, they can cause various infections, illness and in extreme cases can result in 
death. Proper identification of microorganisms and consequent treatment is needed for 
patient welfare. Clearly, early identification will lead to more effective treatment. 
Among the Healthcare-associated infections (HAIs), surgical site infections (SSIs) 
is critical and results in delayed patient recovery and huge financial burden to them. A 
foaming Betadine Spray is tested in-vitro against commercially available preoperative 
surgical site preparation techniques on two different substrates, namely, agar plates and 
porcine skin to ensure the increased effectiveness of preoperative surgical site preparation. 
It is observed that the foaming Betadine Spray has a strong antibacterial effect on the 
bacteria tested. The agar plates as a substrate having smooth surface can be thought to be 
an ideal case, where all the bacteria are killed when in contact with the foaming Betadine 
Spray. However, the porcine skin proves to be a more realistic model replicating the human 
skin; we observe a 2-log reduction in bacterial numbers. There is no statistically significant 
difference between our method and the commercially available technique. This is a 
preliminary study, and further studies need to be conducted on studies on animals/ humans 
to ascertain the efficacy of the foam. 
In addition to looking at SSIs, the research project also involved development and 
optimization of a rapid, cost-effective microbiological platform for detection of viable, 
microorganisms having long generation times like mycobacteria, based on electrical 
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impedance spectroscopy. Several techniques are available in the market for identification 
and detection of mycobacteria that are responsible for various infectious diseases like 
tuberculosis. These methods may be culture-based, microscopy-dependent, serological-
based, molecular-based or proteomics-based techniques. Each method has its pros and 
cons. It is worthwhile to note that time taking culture-based method is still considered the 
reference standard. 
 Our technique involves combining impedance spectroscopy to the culture-based 
technology to decrease the time-to-detection of microorganisms significantly. This 
technique involves measuring the bulk capacitance of the mycobacteria in a suspension 
over time. When an AC field is applied to a bacterial suspension, the bacterial cell 
membrane acts as an interface, and thus acts as a capacitor (stores charge). This 
phenomenon is only observed in the case of viable/ living bacteria. The cell membrane of 
non-viable/ dead cell is compromised, and it is not able to store charges under an applied 
AC field. Thus, using electrical impedance spectroscopy, we can distinguish between live/ 
viable and non-viable bacteria. When such a bacterial suspension is loaded into a thin, long 
channel of a microfluidic cassette, the bulk capacitance solely due to the bacteria can be 
ascertained. Any change in the number of bacteria (growth/ death) will result in a change 
in the bulk capacitance reading from the baseline value over time.  
This technique is very different from the commercial, culture-based automated 
systems currently available in the market for detection of mycobacteria. These automated 
systems for detection of mycobacteria are based on detection of the metabolites produced 
by the bacteria or detection of changes in the media like pH, pressure due to bacterial 
metabolism. Though sensitive, these systems take a very long time to detect the presence 
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of mycobacteria. This is so because of the long doubling times, it takes a long time for the 
bacteria to grow and generate metabolic changes in the media that reach the detection 
threshold of the instrument and can be ascertained by it. Thus, using our technique (our 
threshold of detection is significantly lower than the commercially available culture-based 
instruments). We can get a reduction of ~50% in time-to-detection when compared with 
the commercially available culture-based automated system. 
The currently available culture-based systems are based on detection of 
mycobacteria growth/ metabolic products in the media. However, we have successfully 
demonstrated that detection of mycobacteria based on their death as opposed to growth (as 
is used in most systems) is much faster. This is based on the insight that killing can be 
initiated much faster than cell growth for organisms having long generation times. This 
information is crucial for mycobacteria like M. tuberculosis which has a doubling time of 
~24 hours. On exposure to antibiotics, bacterial cells are killed at a much faster rate in 
comparison to the growth rate of bacterial cells in the absence of antibiotics. The dead 
bacterial cells lose their ability to store charge when an AC field is applied. This results in 
the decrease in the bulk capacitance of the system. By observing the change in this 
parameter, we can ascertain the TTD in 3hours or less. 
However, our platform is in its initial developmental phase. Small aliquots need to 
be withdrawn at regular intervals of time from the main suspension and loaded for 
spectroscopic reading. This manual intervention is labor intensive and can also lead to 
sample contamination. Further optimization with automation of the technique is needed to 
supplement the current technique and make it user-friendly. An automated system with the 
automatic withdrawal of aliquots at regular intervals of time can minimize human 
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intervention. Moreover, as the system will be enclosed, the chances of contamination can 
also be reduced. Such an automated system will be comparable to working with those 
systems which are currently being used but prove to be much faster. 
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